

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2014/154612 A1

(43) International Publication Date
2 October 2014 (02.10.2014)

WIPO | PCT

(51) International Patent Classification:

C07D 413/14 (2006.01) A61K 31/422 (2006.01)
C07D 403/04 (2006.01) A61K 31/4245 (2006.01)
C07D 413/04 (2006.01)

(74) Agent: POMERANC, Didier; Grenzacherstrasse 124, CH-4070 Basel (CH).

(21) International Application Number:

PCT/EP2014/055797

(22) International Filing Date:

24 March 2014 (24.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13161176.6 26 March 2013 (26.03.2013) EP

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL PYRIDINE DERIVATIVES




(57) Abstract: The invention relates to a compound of formula (I); wherein A and R¹ to R⁴ are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

WO 2014/154612 A1

Novel pyridine derivatives

The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to compounds that are preferential agonists of the Cannabinoid Receptor 2.

5 The invention relates in particular to a compound of formula (I)




wherein


A is A1, A2, A3, A4 A5, A6, A7 or A8




A1




A2




A3




A4




A5



A6



A7



A8

;

10 R¹ is hydrogen or halogen;

R² is halogen, cycloalkyl, haloazetidinyl, 6-oxa-1-aza-spiro[3.3]heptyl or alkylsulfonyl;

- 2 -

R³ is -OR⁸, pyrrolidinyl, halopyrrolidinyl, hydroxypyrrrolidinyl, morpholinyl, cycloalkylsulfonyl, alkoxyazetidinyl, 2-oxa-6-aza-spiro[3.3]heptyl or 2-oxa-7-azaspiro[3.4]heptyl;

5 R⁴ is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl, hydroxycycloalkyl, alkylcycloalkyl, aminocarbonylcycloalkyl, phenyl, phenylalkyl, alkyloxetanyl, azetidinyl or aminoxyetanyl;

R⁵ is hydrogen, alkyl or alkyloxadiazolyl;

or R⁴ and R⁵, together with the carbon atom to which they are attached, form cycloalkyl;

10 R⁶ is alkyl;

R⁷ is alkyl; and

15 R⁸ is haloalkyl, alkoxyalkyl, cycloalkylalkyl, haloalkyl, halophenyl, oxetanyl, oxetanylalkyl, alkyloxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl, alkylsulfonylphenyl, alkylpyrrolidinyl, alkylpyrrolidinylalkyl, azetidinyl, morpholinylalkyl, tetrahydropyranyl, pyrrolidinylalkyl, piperidinyl, piperidinylalkyl, alkylpiperidinylalkyl, alkylpiperidinyl, dialkylaminoalkyl, pyridinylalkyl, halooxetanylalkyl, dialkyloxazolylalkyl, alkyloxazolylalkyl, halopyridinylalkyl or morpholinyl;

or a pharmaceutically acceptable salt or ester thereof.

20 The compound of formula (I) is particularly useful in the treatment or prophylaxis of e.g. pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, 25 systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, 30 transient ischemic attack or uveitis.

The compound of formula (I) is in particular useful in the treatment or prophylaxis of diabetic retinopathy, retinal vein occlusion or uveitis.

The cannabinoid receptors are a class of cell membrane receptors belonging to the G protein-coupled receptor superfamily. There are currently two known subtypes, termed Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2). The CB1 receptor is mainly expressed in the central nervous (i.e. amygdala cerebellum, hippocampus) system 5 and to a lesser amount in the periphery. CB2, which is encoded by the CNR2 gene, is mostly expressed peripherally, on cells of the immune system, such as macrophages and T-cells (Ashton, J. C. et al. *Curr Neuropharmacol* 2007, 5(2), 73-80; Miller, A. M. et al. *Br J Pharmacol* 2008, 153(2), 299-308; Centonze, D., et al. *Curr Pharm Des* 2008, 14(23), 2370-42), and in the gastrointestinal system (Wright, K. L. et al. *Br J Pharmacol* 2008, 10 153(2), 263-70). The CB2 receptor is also widely distributed in the brain where it is found primarily on microglia and not neurons (Cabral, G. A. et al. *Br J Pharmacol* 2008, 153(2): 240-51).

The interest in CB2 receptor agonists has been steadily on the rise during the last decade (currently 30-40 patent applications/year) due to the fact that several of the early 15 compounds have been shown to have beneficial effects in pre-clinical models for a number of human diseases including chronic pain (Beltramo, M. *Mini Rev Med Chem* 2009, 9(1), 11-25), atherosclerosis (Mach, F. et al. *J Neuroendocrinol* 2008, 20 Suppl 1, 53-7), regulation of bone mass (Bab, I. et al. *Br J Pharmacol* 2008, 153(2), 182-8), neuroinflammation (Cabral, G. A. et al. *J Leukoc Biol* 2005, 78(6), 1192-7), 20 ischemia/reperfusion injury (Pacher, P. et al. *Br J Pharmacol* 2008, 153(2), 252-62), systemic fibrosis (Akhmetshina, A. et al. *Arthritis Rheum* 2009, 60(4), 1129-36; Garcia-Gonzalez, E. et al. *Rheumatology (Oxford)* 2009, 48(9), 1050-6), liver fibrosis (Julien, B. et al. *Gastroenterology* 2005, 128(3), 742-55; Munoz-Luque, J. et al. *J Pharmacol Exp Ther* 2008, 324(2), 475-83).

25 Ischemia/reperfusion (I/R) injury is the principal cause of tissue damage occurring in conditions such as stroke, myocardial infarction, cardiopulmonary bypass and other vascular surgeries, and organ transplantation, as well as a major mechanism of end-organ damage complicating the course of circulatory shock of various etiologies. All these conditions are characterized by a disruption of normal blood supply resulting in an 30 insufficient tissue oxygenation. Re-oxygenation e.g., reperfusion is the ultimate treatment to restore normal tissue oxygenation. However the absence of oxygen and nutrients from blood creates a condition in which the restoration of circulation results in further tissue damage. The damage of reperfusion injury is due in part to the inflammatory response of damaged tissues. White blood cells, carried to the area by the newly returning blood, 35 release a host of inflammatory factors such as interleukins as well as free radicals in response to tissue damage. The restored blood flow reintroduces oxygen within cells that damages cellular proteins, DNA, and the plasma membrane.

Remote ischemic preconditioning (RIPC) represents a strategy for harnessing the body's endogenous protective capabilities against the injury incurred by ischemia and reperfusion. It describes the intriguing phenomenon in which transient non-lethal ischemia and reperfusion of one organ or tissue confers resistance to a subsequent episode of 5 "lethal" ischemia reperfusion injury in a remote organ or tissue. The actual mechanism through which transient ischemia and reperfusion of an organ or tissue confers protection is currently unknown although several hypotheses have been proposed.

The humoral hypothesis proposes that the endogenous substance (such as adenosine, bradykinin, opioids, CGRP, endocannabinoids, Angiotensin I or some other as yet 10 unidentified humoral factor) generated in the remote organ or tissue enters the blood stream and activates its respective receptor in the target tissue and thereby recruiting the various intracellular pathways of cardioprotection implicated in ischemic preconditioning.

Recent data indicates that endocannabinoids and their receptors, in particular CB2 might be involved in pre-conditioning and contribute to prevent reperfusion injury by 15 downregulation of the inflammatory response (Pacher, P. et al. Br J Pharmacol 2008, 153(2), 252-62). Specifically, recent studies using CB2 tool agonists demonstrated the efficacy of this concept for reducing the I/R injury in the heart (Defer, N. et al. Faseb J 2009, 23(7), 2120-30), the brain (Zhang, M. et al. J Cereb Blood Flow Metab 2007, 27(7), 1387-96), the liver (Batkai, S. et al. Faseb J 2007, 21(8), 1788-800) and the kidney (Feizi, 20 A. et al. Exp Toxicol Pathol 2008, 60(4-5), 405-10).

Moreover, over the last few years, a growing body of literature indicates that CB2 can also be of interest in sub-chronic and chronic setting. Specific upregulation of CB1 and CB2 has been shown to be associated in animal models of chronic diseases associated with 25 fibrosis (Garcia-Gonzalez, E. et al. Rheumatology (Oxford) 2009, 48(9), 1050-6; Yang, Y. Y. et al. Liver Int 2009, 29(5), 678-85) with a relevant expression of CB2 in myofibroblasts, the cells responsible for fibrosis progression.

Activation of CB2 receptor by selective CB2 agonist has in fact been shown to exert anti-fibrotic effect in diffuse systemic sclerosis (Garcia-Gonzalez, E. et al. Rheumatology (Oxford) 2009, 48(9), 1050-6) and CB2 receptor has emerged as a critical target in 30 experimental dermal fibrosis (Akhmetshina, A. et al. Arthritis Rheum 2009, 60(4), 1129-36) and in liver pathophysiology, including fibrogenesis associated with chronic liver diseases (Lotersztajn, S. et al. Gastroenterol Clin Biol 2007, 31(3), 255-8; Mallat, A. et al. Expert Opin Ther Targets 2007, 11(3), 403-9; Lotersztajn, S. et al. Br J Pharmacol 2008, 153(2), 286-9).

The compounds of the invention bind to and modulate the CB2 receptor and have lower CB1 receptor activity.

In the present description the term “alkyl”, alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, particularly a straight or branched-chain alkyl group with 1 to 6 carbon atoms and more particularly a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched-chain C₁-C₈ alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, particularly methyl, ethyl, propyl, butyl and pentyl more particularly methyl, ethyl, propyl, isopropyl, isobutyl, tert.-butyl and isopentyl. Particular examples of alkyl are methyl, ethyl, isopropyl, isobutyl and tert.-butyl, in particular methyl, ethyl and tert.-butyl.

The term “cycloalkyl”, alone or in combination, signifies a cycloalkyl ring with 3 to 8 carbon atoms and particularly a cycloalkyl ring with 3 to 6 carbon atoms. Examples of cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloheptyl and cyclooctyl. Particular examples of “cycloalkyl” are cyclopropyl, cyclopentyl and cyclohexyl, in particular cyclopropyl and cyclohexyl.

The term “alkoxy”, alone or in combination, signifies a group of the formula alkyl-O- in which the term “alkyl” has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy. Particular “alkoxy” are methoxy, ethoxy and butoxy, and in particular methoxy and butoxy.

The term “oxy”, alone or in combination, signifies the -O- group.

The terms “halogen” or “halo”, alone or in combination, signifies fluorine, chlorine, bromine or iodine and particularly fluorine, chlorine or bromine, more particularly fluorine and chlorine. The term “halo”, in combination with another group, denotes the substitution of said group with at least one halogen, particularly substituted with one to five halogens, particularly one to four halogens, i.e. one, two, three or four halogens. A particular “halogen” is fluorine.

The term “haloalkyl”, alone or in combination, denotes an alkyl group substituted with at least one halogen, particularly substituted with one to five halogens, particularly one to three halogens. Particular “haloalkyl” are trifluoroethyl, trifluoromethyl, trifluoropropyl and difluoroethyl, more particularly trifluoroethyl and difluoroethyl.

A particular “halophenyl” is fluorophenyl. A particular haloazetidinyl is difluoroazetidinyl, in particular 3,3-difluoro-azetidin-1-yl. A particular halopyrrolidinyl is

difluoropyrrolidinyl, in particular 3,3-difluoro-pyrrolidin-1-yl, or tetrafluoropyrrolidinyl, in particular 3,3,4,4-tetrafluoropyrrolidin-1-yl. A particular halooxetanyl is fluorooxetanyl. A particular halopyridinyl is fluoropyridinyl.

5 The terms "hydroxyl" and "hydroxy", alone or in combination, signify the -OH group.

The term "carbonyl", alone or in combination, signifies the -C(O)- group.

The term "amino", alone or in combination, signifies the primary amino group (-NH₂), the secondary amino group (-NH-), or the tertiary amino group (-N-).

The term "sulfonyl", alone or in combination, signifies the -S(O)₂- group.

10 The term "pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, particularly hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, 15 pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine. In addition these salts may be prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, 20 potassium, lithium, ammonium, calcium, magnesium salts. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, 25 piperidine, polyamine resins. The compound of formula (I) can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula (I) are the salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and methanesulfonic acid.

"Pharmaceutically acceptable esters" means that the compound of general formula (I) 30 may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compound of general

formula (I), similar to the metabolically labile esters, which are capable of producing the parent compound of general formula (I) in vivo, are within the scope of this invention.

If one of the starting materials or compounds of formula (I) contain one or more functional groups which are not stable or are reactive under the reaction conditions of one or more reaction steps, appropriate protecting groups (as described *e.g.* in “Protective Groups in Organic Chemistry” by T. W. Greene and P. G. M. Wuts, 3rd Ed., 1999, Wiley, New York) can be introduced before the critical step applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature. Examples of protecting groups are tert-butoxycarbonyl (Boc), 9-fluorenylmethyl carbamate (Fmoc), 2-trimethylsilylethyl carbamate (Teoc), carbobenzyloxy (Cbz) and p-methoxybenzyloxycarbonyl (Moz).

The compound of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.

The term “asymmetric carbon atom” means a carbon atom with four different substituents. According to the Cahn-Ingold-Prelog Convention an asymmetric carbon atom can be of the “R” or “S” configuration.

The invention relates in particular to:

20 A compound of formula (I) wherein A is A1 or A2;

A compound of formula (I) wherein R¹ is hydrogen or chloro;

A compound of formula (I) wherein R¹ is hydrogen;

A compound of formula (I) wherein R² is cycloalkyl, bishalo-azetidinyl or alkylsulphonyl;

25 A compound of formula (I) wherein R² is cycloalkyl;

A compound of formula (I) wherein R² is cyclopropyl;

A compound of formula (I) wherein R³ is -OR⁸ or pyrrolidinyl;

A compound of formula (I) wherein R³ is -OR⁸;

A compound of formula (I) wherein R⁴ is alkyl;

A compound of formula (I) wherein R⁴ is butyl, in particular tert.-butyl;

A compound of formula (I) wherein R⁵ is hydrogen, ethyl or methyloxadiazolyl, or R⁴ and R⁵, together with the carbon atom to which they are attached, form cyclohexyl;

A compound of formula (I) wherein R⁶ is methyl;

5 A compound of formula (I) wherein R⁷ is methyl or isopropyl;

A compound of formula (I) wherein R⁸ is haloalkyl, alkoxyalkyl, cycloalkylalkyl, haloalkyl, halophenyl, oxetanyl, oxetanylalkyl, alkyloxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl, alkylsulfonylphenyl, alkylpyrrolidinyl, alkylpyrrolidinylalkyl, azetidinyl, morpholinylalkyl, tetrahydropyranyl, pyrrolidinylalkyl, 10 piperidinyl, piperidinylalkyl, alkylpiperidinylalkyl, alkylpiperidinyl, dialkylaminoalkyl, pyridinylalkyl, haloxyetanylalkyl, dialkyloxazolylalkyl or alkyloxazolylalkyl;

A compound of formula (I) wherein R⁸ is haloalkyl, alkoxyalkyl, halophenyl, alkylsulphonyl, sulphonylphenyl, alkylpyrrolidinyl, alkoxyalkylpyrrolidinyl, 2-oxa-6-aza-spiro[3.3]heptanyl, alkyloxetanylalkyl, oxetanylalkyl, tetrahydrofuranyl, 15 tetrahydrofuranylalkyl, tetrahydropyranyl or alkyloxadiazolyl;

A compound of formula (I) wherein R⁸ is haloalkyl, alkoxyalkyl, halophenyl, alkyloxetanylalkyl, oxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl or tetrahydropyranyl;

20 A compound of formula (I) wherein R⁸ is trifluoromethyl, ethoxyethyl, methoxybutyl, fluorophenyl, oxetanylmehtyl, methyloxetanylmehtyl, tetrahydrofuranyl, tetrahydrofuranylmehtyl or tetrahydropyranyl;

A compound of formula (I) wherein R⁸ is haloalkyl, alkoxyalkyl, halophenyl, alkyloxetanylalkyl, oxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl, tetrahydropyranyl, halopyridinylalkyl or morpholinyl; and

25 A compound of formula (I) wherein R⁸ is trifluoromethyl, ethoxyethyl, methoxybutyl, fluorophenyl, oxetanylmehtyl, methyloxetanylmehtyl, tetrahydrofuranyl, tetrahydrofuranylmehtyl, tetrahydropyranyl, difluoroethyl, fluoropyridinylmethyl or morpholinyl.

Particular R⁴ are methyl, ethyl, isopropyl, tert.-butyl, trifluoromethyl, cyclopropyl, 30 cyclopentyl, methylcyclopropyl, aminocarbonylcyclopropyl, hydroxymehtyl, hydroxypropyl, hydroxycyclopropyl, methoxymethyl, phenyl, phenylmethyl, methyloxetanyl, azetidinyl, methyloxetanyl and aminoxyetanyl.

In the definition of R⁴, tert.-butyl is a particular butyl.

The invention further relates to a compound of formula (I) selected from:

5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole;

5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-phenyl-1,2,4-oxadiazole;

5 3-cyclopropyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-cyclopentyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-benzyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

10 3-tert-butyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-cyclopropyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-(trifluoromethyl)-1,2,4-oxadiazole;

15 5-cyclopropyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

20 3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(methoxymethyl)-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-ethyl-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

25 3-cyclopropyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole;

3-tert-butyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]methanol;

5 3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(trifluoromethyl)-1,2,4-oxadiazole;

(4S)-4-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,5-dihydro-1,3-oxazole;

10 2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4-ethyl-4,5-dihydro-1,3-oxazole;

2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;

1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

15 3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropane-1-carboxamide;

20 2-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propan-2-ol;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

25 5-(azetidin-3-yl)-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;

5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

1-[6-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-4-(cyclopropylmethoxy)pyridin-3-yl]-6-oxa-1-azaspiro[3.3]heptane;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

10 1-[3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5,5-dimethyl-4H-1,3-oxazole;

5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-propan-2-yl-1,2,4-oxadiazole;

20 5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-methylsulfonylpyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

25 1-[3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5 3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

10 3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(4-fluorophenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole

3-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]oxetan-3-amine;

5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-(5-tert-butyl-1H-imidazol-2-yl)-5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine;

5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,3-oxazole;
2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;
5 5-tert-butyl-3-[5-methylsulfonyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;
2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-ethyl-4-methyl-1H-imidazol-5-one;
2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-(2-methylpropyl)-1H-imidazol-5-one;
10 2-[5-bromo-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;
5-tert-butyl-3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;
3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-cyclopropyl-1,2,4-oxadiazole;
15 5-cyclopropyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;
1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]pyrrolidin-3-ol;
5-tert-butyl-3-[5-cyclopropyl-4-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;
20 5-tert-butyl-3-[5-cyclopropyl-4-(4-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole;
7-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-7-azaspiro[3.4]octane;
5-tert-butyl-3-[5-cyclopropyl-4-(3,3-difluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;
25 4-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]morpholine;
5-tert-butyl-3-(5-cyclopropyl-4-pyrrolidin-1-ylpyridin-2-yl)-1,2,4-oxadiazole;
5-tert-butyl-3-(5-cyclopropyl-4-cyclopropylsulfonylpyridin-2-yl)-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxyazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

6-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-6-azaspiro[3.3]heptane;

5 5-tert-butyl-3-[5-cyclopropyl-4-(2-ethoxyethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxybutan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[2-[(2-methylpropan-2-yl)oxy]ethoxy]pyridin-2-yl]-1,2,4-oxadiazole;

10 5-tert-butyl-3-[5-cyclopropyl-4-[1-[(2-methylpropan-2-yl)oxy]propan-2-yloxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxypropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-cyclopropyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-(1-propan-2-ylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-pyrrolidin-1-ylethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-(2-piperidin-1-ylethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-piperidin-1-ylpropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(1-methylpiperidin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

2-tert-butyl-5-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,3,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxy-N,N-diethylpropan-1-amine;

10 3-[[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxymethyl]morpholine;

4-[2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxyethyl]morpholine;

5-tert-butyl-3-(5-cyclopropyl-4-piperidin-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-[(3-fluorooxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-[(5-methyl-1,2-oxazol-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-5H-1,3-oxazol-4-yl]-5-methyl-1,2,4-oxadiazole;

- 16 -

5-tert-butyl-3-(6-chloro-5-cyclopropyl-4-(4-fluorobenzyloxy)pyridin-2-yl)-1,2,4-oxadiazole;

2-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,3,4-oxadiazole;

5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-fluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole; and

5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole.

The invention relates in particular to a compound of formula (I) selected from:

5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-ethoxyethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)pyridin-2-yl]-1,2,4-oxadiazole;

20 and

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole.

The invention further relates in particular to a compound of formula (I) selected from

5-tert-butyl-3-[5-cyclopropyl-4-[(5-fluoropyridin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,3,4-oxadiazole;

3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole;

5 3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole; and

3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole.

The invention further relates in particular to a compound of formula (I) selected from

10 5-tert-butyl-3-[5-cyclopropyl-4-[(5-fluoropyridin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole; and

3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole.

The synthesis of the compound of formula (I) can, for example, be accomplished

15 according to the following schemes.

Unless otherwise specified, R² to R⁸ and A have in the following schemes the meaning as defined above. In schemes 1 to 15, R¹ is hydrogen; in scheme 16, R¹ is halogen.


20 Following the procedure according to scheme 1, compound **AA** can be used as starting material. **AA** is either commercially available, described in the literature or can be synthesized by a person skilled in the art.

25 Compound **AB** can be prepared from **AA** by reaction with a suitably substituted alcohol as described in the claims, in the presence of a base, for example sodium hydride, with or without an inert solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux temperature of the solvent (step a).

30 Conversion of compound **AB** to compound **AC** can be prepared by coupling a suitably substituted cycloalkyl metal species (e.g. a trifluoroborate [BF₃]⁻K⁺, a boronic acid B(OH)₂ or a boronic acid pinacol ester) (step b), e.g. an organotrifluoroborate potassium salt in the presence of a palladium catalyst such as palladium(II)acetate / butyl-1-adamantylphosphine and a base such as cesium carbonate in an inert solvent such as toluene at temperatures between 50 °C and the boiling temperature of the solvent, or an

arylboronic acid or arylboronic acid ester in the presence of a suitable catalyst, in particular a palladium catalyst and more particularly palladium(II)acetate / triphenylphosphine mixtures or palladium(II)chloride-dppf (1,1'-bis(diphenylphosphino)ferrocene) complexes and a base such as triethylamine, sodium carbonate or potassium phosphate in an inert solvent such as dimethylformamide, toluene, tetrahydrofuran, acetonitrile or dimethoxyethane.

Scheme 1



10 **AC** can be selectively halogenated on position 2 to give **AD** for example by treatment of N,N-dimethylethanolamine with butyl lithium on **AC** followed by addition of a source of Bromine, e.g. 1,2-dibromotetrachloroethane (step c).

15 Compound **AE** can be prepared from **AD** by addition of cyanide source, e.g. zinc cyanide or copper cyanide in presence of a palladium catalyst such as palladium triphenylphosphine tetrakis or tris(dibenzylideneacetone)dipalladium(0) and dppf, in a solvent such as DMF or dioxane and refluxed to the solvent boiling point temperature (step d).

Hydrolysis of compound **AE** lead to the picolinic acid **AF** and can be performed under acidic or basic conditions known to a person skilled in the art, e.g. with aqueous solution of hydrochloric acid at 100°C (step e).

Compounds of formula **I** with A1, can be prepared from compounds of formula **AF**

5 by amide coupling methods known to a person skilled in the art, with the suitably substituted hydroxyamidine commercially available leading to intermediate **AF[Int]**(step f), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF(step g).


Compound **AE** can be converted to **AG** by treatment with hydroxylamine

10 hydrochloride in presence of base such as triethylamine (step h).

Cyclisation to compound **I** with A2 can be performed by amide coupling methods known to a person skilled in the art, with the suitably substituted commercially available carboxylic acid to give intermediate **AG[Int]**(step i), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step j).

15 Alternatively, following the procedure according to scheme 2, compound **BA** can be prepared from **AC** by oxidation with a suitable oxidizing reagent under conditions known to a person skilled in the art, e.g. by treatment with 3-chloro perbenzoic acid in dichloromethane at ambient temperature (step a).

Scheme 2



Compound **AE** can be then prepared from **BA** by a cyanation method known to a person skilled in the art, such treatment with trimethylsilane carbonitrile followed by addition of dimethylcarbamic chloride in a solvent such as DCM.

Compound **AE** can be further elaborated to compounds **I** with A1 or A2, as


25 described in scheme 1, step e and f or g and h.

Alternatively, according to scheme 3, especially when R² was a substituent sensitive to oxidation such as groups with nitrogen, compound **CA** can be prepared from **AB** by oxidation with a suitable oxidizing reagent under conditions known to a person skilled in

- 20 -

the art (step a), e.g. by treatment with 3-chloro perbenzoic acid in dichloromethane at ambient temperature.

Scheme 3




5 Compound **CB** can be then prepared from **CA** by a cyanation method known to a person skilled in the art, such treatment with trimethylsilanecarbonitrile followed by addition of dimethylcarbamic chloride in a solvent such as DCM (step b).

10 Compound **AE** can be obtained from compound **CB** by substituting with an amine or salt of an amine such difluoroazetidine hydrochloride, using Buchwald reaction conditions known to a person skilled in the art (step c), such as Cs_2CO_3 , palladium acetate and BINAP in a solvent such as toluene under reflux.

Compound **AE** can be further elaborated to compounds **I** with A1 or A2, as described in scheme 1, step e and f or g and h.

15 Alternatively, following the procedure according to scheme 4, compound **DA** can be prepared from **CB** by treatment with hydroxylamine hydrochloride in presence of base such as triethylamine in a solvent such as DCM (step a).

Scheme 4



20 Cyclisation of compound **DA** to compound **DB** with heterocycle type A2 can be performed by amide coupling methods known to a person skilled in the art, with the suitably substituted commercially available carboxylic acid to give intermediate **DA[Int]** (step b), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step c).

Compound **I** can be obtained from compound **DB** by substituting with an amine or salt of an amine such difluoroazetidine hydrochloride, using Buchwald reaction conditions known to a person skilled in the art (step d), such as Cs_2CO_3 , palladium acetate and BINAP in a solvent such as toluene under reflux. .

5 Compound **AE** can be further elaborated to compounds **I** with heterocycle type A2 by coupling R^2 where R^2 is either an alkyl chain using similar method as described in scheme 1 step b; or R^2 is an amine or the corresponding salt using Buchwald reaction conditions as described in scheme 3 step c.

Following the procedure according to scheme 5, compound **EA** can be used as
10 starting material. **EA** is either commercially available, described in the literature or can be synthesized by a person skilled in the art.


Compound **EB** can be obtained from compound **EA** (step a) by coupling with an alkyl chain using similar method as described in scheme 1 step b.

15 Compound **EC** can be prepared from **EB** by cyanation reaction methods, e.g. zinc cyanide or copper cyanide in presence of a palladium catalyst such as palladium triphenylphosphine tetrakis or tris(dibenzylideneacetone)dipalladium(0) and dppf, in a solvent such as DMF or dioxane and refluxed to the solvent boiling point temperature (step b).

20 Compound **EC** can be converted to **ED** by treatment with hydroxylamine hydrochloride in presence of base such as triethylamine in a solvent such as DCM (step c).

25 Cyclisation of compound **ED** to compound **EE** with heterocycle type A2 can be performed by amide coupling methods known to a person skilled in the art, with the suitably substituted commercially available carboxylic acid to give intermediate **ED[Int]**(step d), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step e).

Scheme 5



Compound **I** can be obtained from compound **EE** (step *f*) by reaction with a suitably substituted alcohol as described in the claims, in the presence of a base, for example sodium hydride, with or without an inert solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux temperature of the solvent; or by reaction with a suitably substituted amine using a base such as Cs_2CO_3 in a high boiling point solvent such as ethylene glycol or alternatively using Buchwald reaction conditions known to a person skilled in the art, such Cs_2CO_3 , palladium acetate and BINAP in a solvent such toluene under reflux.

Compound **AE** can be prepared from compound **EC** (step g) by reaction with a suitably substituted alcohol as described in the claims, in the presence of a base, for example sodium hydride, with or without an inert solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux 5 temperature of the solvent.

Hydrolysis of compound **AE** lead to the picolinic acid **AF** and can be performed under acidic or basic conditions known to a person skilled in the art, e.g. with aqueous solution of hydrochloric acid at 100°C (step h).

Compounds of formula **EF** can be prepared from compounds of formula **AF** by 10 amide coupling methods known to a person skilled in the art, with the suitably substituted hydrazide commercially available, in an appropriate solvent (step i).


Cyclisation of compound **EF** to compound **I** with heterocycle type A8 can be performed by dehydration methods (step j) known to a person skilled in the art, e.g. treatment of compound **EF** by a reaction mixture of trifluoromethanesulfonic anhydride 15 and triphenylphosphine oxide in a solvent such as DCM.

Following the procedure according to scheme 6 (step a), compound **FA** can be obtained from compound **AA** by coupling R² where R² is an alkyl chain using similar method as described in scheme 1 step b.

Compound **FA** can be selectively carbonylated on position 2 to give **FB** by a method 20 known to a person skilled in the art for example by treatment of N,N-dimethylethanolamine with butyl lithium on **AC** followed by addition of a source of carbon dioxide, e.g. dry ice (step b).

Compound **FC** (with A1), can be prepared from compound **FB** by amide coupling methods known to a person skilled in the art, with the suitably substituted hydroxyamidine 25 commercially available giving intermediate **FB[Int]** (step c), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step d).

Scheme 6




Compound **I** (with A1) can be prepared from compound **FC** by reaction with a 5 suitably substituted alcohol as described in the claims, in the presence of a base, for example sodium hydride, with or without an inert solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux temperature of the solvent (step e).

Following the procedure according to scheme 7 (step a), compound **GA** can be 10 obtained from compound **EA** by coupling with oxetane-3-one using Grignard reaction method known to a person skilled in the art, e.g. isopropyl magnesium chloride lithium chloride complex in a solvent such as THF.

Compound **GB** can be prepared from **GA** by cyanation reaction methods, e.g. zinc 15 cyanide or copper cyanide in presence of a palladium catalyst such as palladium triphenylphosphine tetrakis or tris(dibenzylideneacetone)dipalladium(0) and dppf, in a solvent such as DMF or dioxane and refluxed to the solvent boiling point temperature (step b).

Scheme 7



Compound **GC** can be prepared from **GB** by conversion of the hydroxy to fluorine 5 using fluorinating reagents, such as DAST (step c).

Compound **GC** can be converted to **GD** by treatment with hydroxylamine hydrochloride in presence of base such as triethylamine in a solvent such DCM (step d).


Cyclisation of compound **GD** to compound **GE** with heterocycle type A2 can be performed by amide coupling methods known to a person skilled in the art, with the 10 suitably substituted commercially available carboxylic acid giving intermediate **GD[Int]** (step e), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step f).

Compound **I** (with A2) can be obtained from compound **GE** (step g) by reaction with a suitably substituted alcohol as described in the claims, in the presence of a base, for 15 example sodium hydride, with or without an inert solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux temperature of the solvent.

Following the procedure according to scheme 8, compound **HA** can be used as starting material. **HA** is either commercially available, described in the literature or can be 20 synthesized by a person skilled in the art.

Compound **HB** can be prepared from **HA** by reaction with a suitably substituted alkyl chain with a leaving group, e.g. halogen or triflate, in the presence of a base, for example sodium hydride, in a solvent, for example dimethylformamide, at temperatures ranging from room temperature to the reflux temperature of the solvent (step a).

Scheme 8



Compound **HC** can be prepared from **HB** by cyanation reaction methods known to a person skilled in the art, e.g. zinc cyanide or copper cyanide in presence of a palladium catalyst such as palladium triphenylphosphine tetrakis or tris(dibenzylideneacetone)dipalladium(0) and dppf, in a solvent such as DMF or dioxane and refluxed to the solvent boiling point temperature (step b).


Compound **HC** can be converted to **HD** by treatment with hydroxylamine hydrochloride in presence of base such as triethylamine in a solvent such DCM (step c).

Cyclisation of compound **HD** to compound **I**, with heterocycle type A2 and $R^2=$ chlorine, can be performed by amide coupling methods known to a person skilled in the art, with the suitably substituted commercially available carboxylic acid to give intermediate **HD[Int]** (step d), followed by heating to cyclise to the oxadiazole ring in a high boiling point solvent such as DMF (step e).

Following the procedure according to scheme 9, compound **JA** can be obtained from compound **AF** by amide coupling methods known to a person skilled in the art, with the suitably substituted amine commercially available, in an appropriate solvent such as DCM (step a).

- 27 -

Scheme 9




Cyclisation of compound **JA** to compound **I** with heterocycle type A3 can be performed by dehydration methods (step b) known to a person skilled in the art, e.g. using a mild dehydrating reagent such as Burgess Reagent in a solvent such as THF.

Following the procedure according to scheme 10 (step a), compound **KA** can be obtained from compound **AF** by amide coupling methods known to a person skilled in the art, with the suitably substituted amine commercially available, in an appropriate solvent such as DCM (step a).

10

Scheme 10




Formation of compound **KA** to compound **I** with heterocycle type A4 can be performed by condensation methods known to a person skilled in the art, such use of methanesulfonic acid, in a solvent such as DCM (step b).

15

Following the procedure according to scheme 11 (step a), compound **LA** can be obtained from compound **AE** by amidine formation methods known to a person skilled in the art, e.g. treatment by a reaction mixture of trimethylaluminum on ammonium chloride in a solvent such as toluene.

20

Scheme 11




Conversion of compound **LA** to compound **I** with heterocycle type A5 can be performed by coupling method with an alpha halogeno ketone suitably substituted known to a person skilled in the art, e.g use of a base such as DBU in a solvent such as ethanol giving intermediate **LA[Int]** (step b), and heated to cyclise (step c).

Following the procedure according to scheme 12, compound **MA** can be obtained from compound **AF** (step a) by amide coupling methods known to a person skilled in the art, with the suitably substituted amine, in an appropriate solvent such as THF (step a).

10

Scheme 12




Conversion of compound **MA** to compound **I** with heterocycle type A6 (step b) can be performed by cyclising using a base, e.g. potassium hydroxide in a solvent such as THF at reflux temperature of the solvent.

15

Following the procedure according to scheme 13 (step a), compound **NA** can be obtained from compound **AF** by amide coupling methods known to a person skilled in the art, with the suitably substituted alpha amino alcohol, in an appropriate solvent such as DCM (step a).

20

Scheme 13



- 29 -


Compound **NB** can be prepared from **NA** by oxidation with a suitable oxidizing reagent known to a person skilled in the art (step b), e.g. by treatment with Dess-Martin periodinane in a solvent such as DCM.

Conversion of compound **NB** to compound **I** with heterocycle type A7 (step c) can 5 be performed by cyclisation method known to a person skilled in the art, e.g. treatment with hexachloroethane and triphenylphosphine in as solvent such as acetonitrile.

Following the procedure according to scheme 14, compound **OA** can be obtained from compound **DB** by substitution with a alkylthiol, e.g. methanethiol and heated in an appropriate solvent such as DMF (step a).

10

Scheme 14




Conversion to compound **I** can be performed by oxidation of compound **OA** with a suitable oxidizing reagent under conditions known to a person skilled in the art (step b), e.g. by treatment with 3-chloro perbenzoic acid in dichloromethane at ambient 15 temperature.

Following the procedure described in scheme 15, compound **PA** can be obtained from compound **AF** by amide coupling methods known to a person skilled in the art, with the suitably substituted amine, previuosly prepared by a skilled chemist, in an appropriate solvent such as DCM (step a).

20

25

Scheme 15




Compound **PA** can be converted to compound **PB** (step b) by debenzylation methods known to a person skilled in the art, e.g. treatment by BBr_3 solution in DCM.

5 Compound **PC** can be prepared from compound **PB** by tosylation methods, e.g. 4-methylbenzene-1-sulfonyl chloride with potassium carbonate in presence of dimethylaminopyridine in a solvent such as DCM.

Compound **PC** can be cyclized to compound **I** with heterocycle type A3, by heating in a presence of a base e.g. triethylamine, in a solvent such as DMF.

10 Alternatively, following the procedure according to scheme 14, compound **QA** can be prepared from **I** by oxidation with a suitable oxidizing reagent under conditions known to a person skilled in the art, e.g. by treatment with 3-chloro perbenzoic acid in dichloromethane (step a).


Scheme 16




Compound I can be prepared from QA by chlorination methods known to a person skilled in the art, such as treatment with oxalyl chloride in a solvent such as DCM.

The invention also relates to a process for the manufacture of a compound of formula (I) as defined above comprising one of the following steps:


5 (a) the heating of a compound of formula (A)



(b) the heating of a compound of formula (B)



(c) the reaction of a compound of formula (C)




10

in the presence of haloazetidine or 6-oxa-1-aza-spiro[3.3]heptane, a base and a palladium catalyst;


(d) the reaction of a compound of formula (D)

- 32 -




in the presence of trifluoromethanesulfonic anhydride and triphenylphosphine oxide;

(e) the reaction of a compound of formula (E1) or (E2)




5 in the presence of HOR, haloazetidine, 6-oxa-1-aza-spiro[3.3]heptane or HSO_2R and a base;

(f) the heating of a compound of formula (F)



in the presence of Burgess reagent;


10 (g) the heating of a compound of formula (G)




in the presence of methanesulfonic acid;

- 33 -


(h) the heating of a compound of formula (H)



(j) the heating of a compound of formula (J)




5 (k) the reaction of a compound of formula (K)




in the presence of hexachloroethane, a base and a phosphine;

(l) the reaction of a compound of formula (L)




10 in the presence of an oxidizing agent;

(m) the heating of a compound of formula (M)



in the presence of a base;

(n) the reaction of a compound of formula (N)



5 in the presence of a chlorinating agent and DMF; or

(o) the reaction of a compound of formula (C) as defined above in the presence of HSR and a base, and then an oxidation agent;

wherein A, A1 to A8 and R¹ to R⁴ are as defined above and wherein R is alkyl.

Step (a) is for example carried out at 120 °C.

10 Step (b) is for example carried out at 130 °C.

Step (c) is for example carried out at 130 °C.

Step (d) is carried out for example at room temperature.

In step (e), the base is for example sodium hydride.

15 The Burgess reagent is commonly known to the person skilled in the art, and is methyl N-(triethylammoniumsulfonyl)carbamate.

Step (g) is for example carried out at 40 °C.

Step (h) is for example carried out at 120 °C.

Step (j) is for example carried out at 70 °C.

In step (k), the base is for example triethylamine. The phosphine is for example triphenylphosphine.

Step (l) can be performed with 3-chloro perbenzoic acid, e.g. in dichloromethane, in 5 particular at ambient temperature.

Step (m) is for example carried out at 80 °C, for example in DMF. The base of step (m) is for example triethylamine.

The chlorinating agent is for example oxalyl chloride.

The invention also relates in particular to:

10 The use of a compound of formula (I) for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute 15 allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient 20 ischemic attack or uveitis;

The use of a compound according of formula (I) for the preparation of a medicament for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory 25 bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, 30 amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis;

A compound of formula (I) for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion,

retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy,

5 cardiomypathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis; and

10 A method for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection,

15 chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomypathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or

20 uveitis, which method comprises administering an effective amount of a compound of formula (I) to a patient in need thereof.

The invention particularly relates to a compound of formula (I) for the treatment or prophylaxis of ischemia, reperfusion injury, liver fibrosis or kidney fibrosis, in particular ischemia or reperfusion injury.

25 The invention particularly relates to a compound of formula (I) for the treatment or prophylaxis of myocardial infarction.

The invention further particularly relates to a compound of formula (I) for the treatment or prophylaxis of age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy or uveitis.

The invention further particularly relates to a compound of formula (I) for the treatment or prophylaxis of amyotrophic lateral sclerosis or multiple sclerosis.

The invention is further directed to a compound of formula (I), when manufactured according to a process according to the invention.

Another embodiment of the invention provides a pharmaceutical composition or medicament containing a compound of the invention and a therapeutically inert carrier, diluent or excipient, as well as a method of using the compounds of the invention to prepare such composition and medicament. In one example, the compound of formula (I) 5 may be formulated by mixing at ambient temperature at the appropriate pH, and at the desired degree of purity, with physiologically acceptable carriers, i.e., carriers that are non-toxic to recipients at the dosages and concentrations employed into a galenical administration form. The pH of the formulation depends mainly on the particular use and the concentration of compound, but preferably ranges anywhere from about 3 to about 8. In 10 one example, a compound of formula (I) is formulated in an acetate buffer, at pH 5. In another embodiment, the compound of formula (I) is sterile. The compound may be stored, for example, as a solid or amorphous composition, as a lyophilized formulation or as an aqueous solution.

Compositions are formulated, dosed, and administered in a fashion consistent with 15 good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

20 The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or 25 subcutaneous administration.

The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH 30 modifiers, sweeteners, bulking agents, and further active agents.

A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, 35 Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe,

Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants,

5 sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

The invention will now be illustrated by the following examples which have no
10 limiting character.

Examples

Abbreviations

MPLC= medium pressure liquid chromatography, model Combiflash Companion from TELEDYNE ISCO; MS = mass spectrometry; ESI = electrospray; BINAP= 2,2'-

5 bis(diphenylphosphino)-1,1'-binaphthyl; CDI = 1,1'-carbonyldiimidazole; Cs₂CO₃ = cesium carbonate; DCM = dichloromethane; DIPEA = *N*-ethyl-*N*-isopropylpropan-2-amine; DBU = 1,8-Diazabicyclo[5.4.0]undec-7-ene; DMF = dimethylformamide; DMSO = dimethyl-sulfoxide; dppf = 1,1'-bis(diphenylphosphino)ferrocene; EtOH = ethanol; HATU = 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium


10 hexafluorophosphate(V); HBTU = O-benzotriazole-*N,N,N',N'*-tetramethyl-uronium-hexafluoro-phosphate; HPLC = LC = high performance liquid chromatography; *m*-CPBA = meta-chloroperoxybenzoic acid; MeOH= methanol; NaHCO₃ = sodium hydrogenocarbonate; Na₂SO₄ = sodium sulfate; Pd(OAc)₂= palladium(II) acetate; RT = room temperature; TBTU = O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyl-uronium-tetrafluoroborate; TBME = methyl *tert*-butylether, THF = tetrahydrofuran; TFA = trifluoroacetic acid; TLC = thin layer chromatography; TMS-CN= Trimethylsilyl cyanide.

15

Example 1**5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole**

a) 3-bromo-4-(cyclopropylmethoxy)pyridine

20




To a solution of 3-bromo-4-chloropyridine (CAS 36953-42-1) (8 g, 41.6 mmol, Eq: 1.00) in dry DMF (100 mL) under argon atmosphere at RT was added cyclopropylmethanol (CAS 2516-33-8) (3.15 g, 3.45 mL, 43.6 mmol, Eq: 1.05) and by portions NaH (1.75 g, 43.6 mmol, Eq: 1.05). The resulting reaction was stirred at RT until gas evolution stopped.

25 The reaction mixture was then stirred at 100°C for 3 h and controlled by TLC. The reaction was cooled down to RT, quenched by addition of water and the mixture concentrated in vacuo. The residue was redissolved in ethyl acetate, extracted with aqueous NaHCO₃ 1M, the organic phase dried over Na₂SO₄, filtered and evaporated down to dryness. Flash chromatography with a 120 g SiO₂ column, with an eluent mixture of heptane and ethyl acetate to give 8.25 g of light yellow oil (Yield: 87%). MS (ESI, *m/z*): 228.2 (M).


b) 3-cyclopropyl-4-(cyclopropylmethoxy)pyridine

- 40 -




To a solution of 3-bromo-4-(cyclopropylmethoxy)pyridine (8.1 g, 35.5 mmol, Eq: 1.00) in a mixture of toluene (150 mL) and water (18 mL) was added potassium cyclopropyltrifluoroborate (CAS 1065010-87-8) (5.52 g, 37.3 mmol, Eq: 1.05), Cs_2CO_3 (23.1 g, 71.0 mmol, Eq: 2.0), butyldi-1-adamantylphosphine (382 mg, 1.07 mmol, Eq: 0.03) and $\text{Pd}(\text{OAc})_2$ (159 mg, 710 μmol , Eq: 0.02). The reaction mixture was stirred at 125°C for 7 h. Reaction mixture was cooled down and poured into a separatory funnel, ethyl acetate and water were added. After extraction of the mixture, the organic phase was collected, dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 120 g SiO_2 column, and an eluent mixture of heptane and ethyl acetate gave 4.6 g of the desired product (Yield 68%). MS (ESI, m/z): 190.3 (MH^+).

c) 2-bromo-5-cyclopropyl-4-(cyclopropylmethoxy)pyridine




To a solution of N,N-dimethylethanolamine (1.13 g, 1.28 mL, 12.7 mmol, Eq: 3.0) in hexane (9 mL) under an argon atmosphere at -15°C was slowly added BuLi 1.6M in hexane (15.9 mL, 25.4 mmol, Eq: 6.0) and the reaction mixture was stirred at -15°C for 15 min. Addition of 3-cyclopropyl-4-(cyclopropylmethoxy)pyridine (0.8 g, 4.23 mmol, Eq: 1.00) in dry toluene (5 mL) to the reaction at -15°C was followed by stirring at -15°C for 1 h. Reaction was then cooled down to -78°C and a solution of 1,2-dibromotetrachloroethane (4.13 g, 12.7 mmol, Eq: 3.0) in dry toluene (6 mL) was added. The resulting white suspension was then stirred for 1 h at -78°C and controlled by LC-MS. The reaction was then quenched with water, allowed to warm up to RT and diluted with ethyl acetate. The mixture was poured into a separatory funnel, extracted with aqueous NaHCO_3 1M. The organic phase was dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 70 g SiO_2 column, and an eluent mixture of heptane and ethyl acetate gave 980 mg of colorless oil (Yield 77%). MS (ESI, m/z): 268.1 (M).

d) 5-cyclopropyl-4-(cyclopropylmethoxy)picolinonitrile




To a solution of 2-bromo-5-cyclopropyl-4-(cyclopropylmethoxy)pyridine (1.15 g, 3.65 mmol, Eq: 1.00) in Dioxane (25 mL) under an argon atmosphere was added copper (I) cyanide (1.31 g, 14.6 mmol, Eq: 4.0), tetraethylammonium cyanide (570 mg, 3.65 mmol, Eq: 1.00), dppf (323 mg, 583 μ mol, Eq: 0.16) and $\text{Pd}_2(\text{dba})_3$ (134 mg, 146 μ mol, Eq: 0.04). The resulting reaction mixture was stirred at 110°C for 4 h. Reaction mixture was filtered over a pad of Celite, and the filtrate was poured into a separatory funnel. After dilution with ethyl acetate, extraction with aqueous NaHCO_3 1M, the organic phase was collected, dried and evaporated down to dryness. Flash chromatography with a 50 g SiO_2 column, and an eluent mixture of heptane and ethyl acetate gave 392 mg of the desired product (Yield 50%). MS (ESI, m/z): 215.3 (MH^+).

e) 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid



To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)picolinonitrile (200 mg, 933 μ mol, Eq: 1.00) in water (4 mL) was added potassium hydroxide (786 mg, 14.0 mmol, Eq: 15.0). The reaction was stirred at 110°C overnight and monitored by TLC. KOH was neutralized using HCl aqueous solution and the pH was adjusted to 1-2. Afterwards an extraction with DCM/MeOH (4:1) was made and the organic phase was collected, dried and the solvent evaporated. The crude material was purified by MPLC ISCO on SiO_2 column giving 200 mg of compound as a white powder (Yield 92%). MS (ESI, m/z): 234.6 (MH^+).

f) 5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole




- 42 -

In a micro-wave vial with DMF (1.5 mL), 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid (46.7 mg, 200 μ mol, Eq: 1.00) was combined with CDI (32.4 mg, 200 μ mol, Eq: 1.0). The reaction mixture was stirred for 30 min at room temperature under Argon. N'-hydroxyacetimidamide (CAS 22059-22-9) (14.8 mg, 200 μ mol, Eq: 1.0) was added. The 5 reaction mixture was stirred for 1 h, and then heated to 130°C with microwave for another 1 h. The reaction was controlled by LC-MS which showed complete conversion. The reaction mixture was directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 272.5 (MH $+$).

Example 2


10 **5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-phenyl-1,2,4-oxadiazole**



The title compound was synthesized in analogy to Example 1f, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid and N'-hydroxybenzimidamide (CAS 613-92-3) as starting materials, and directly purified by preparative HPLC without any work-up. MS 15 (ESI, *m/z*): 334.5 (MH $+$).

Example 3

3-cyclopropyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 1f, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid and N'-hydroxycyclopropanecarboximidamide (CAS 51285-13-3) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 298.5 (MH $+$).

Example 4

3-cyclopentyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole


- 43 -



The title compound was synthesized in analogy to Example 1f, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid and N'-hydroxycyclopentanecarboximidamide (CAS 99623-12-8) as starting materials, and directly purified by preparative HPLC without any
5 work-up. MS (ESI, m/z): 326.3 (MH $^+$).

Example 5


3-benzyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 1f, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid and N'-hydroxy-2-phenylacetimidamide (CAS 19227-11-3) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 348.2 (MH $^+$).

Example 6

3-tert-butyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole




15

The title compound was synthesized in analogy to Example 1f, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid and N'-hydroxypivalimidamide (CAS 42956-75-2) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 314.2 (MH $^+$).


Example 7**3-cyclopropyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole**

a) 3-bromo-4-(2,2,2-trifluoroethoxy)pyridine



5 To a solution of 3-bromo-4-chloropyridine (CAS 36953-42-1) (25 g, 130 mmol, Eq: 1.00) in DMF (333 mL) was added 2,2,2-trifluoroethanol (CAS 75-89-8) (19.5g, 195 mmol, Eq: 1.5) and potassium tert-butoxide (21.9 g, 195 mmol, Eq: 1.5). The reaction was stirred overnight at 110°C. The solvent was partially evaporated and partitioned between NaHCO₃ aqueous saturated solution and ethyl acetate. The organic layer was dried over Na₂SO₄ and 10 evaporated. Product used as a crude (85% yield). MS (ESI, *m/z*): 257.3 (MH⁺).


b) 3-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridine



To a solution of 3-bromo-4-(2,2,2-trifluoroethoxy)pyridine (28.44 g, 88.9 mmol, Eq: 1.00) in a mixture of toluene (275 mL) and water (32.5 mL) was added potassium 15 cyclopropyltrifluoroborate (CAS 1065010-87-8) (14.5 g, 97.8 mmol, Eq: 1.1), palladium (II) acetate (798 mg, 3.55 mmol, Eq: 0.04), butyldi-1-Adamantylphosphine (1.27 g, 3.55 mmol, Eq: 0.04) and Cs₂CO₃ (72.4 g, 222 mmol, Eq: 2.5) under an argon atmosphere. The reaction mixture was stirred over night at 115°C and controlled by TLC. The reaction mixture was extracted with ethyl acetate and water. The organic phase was dried over 20 Na₂SO₄ and evaporated down to dryness. The crude material was purified by MPLC ISCO on SiO₂ column with a gradient heptane in ethyl acetate giving yellow viscous oil (Yield 72%). MS (ESI, *m/z*): 218.5 (MH⁺).

c) 3-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridine 1-oxide


- 45 -



To a solution of 3-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridine (13.89g, 64 mmol, Eq: 1.00) in DCM (355 mL) was added *m*-CPBA (16.6 g, 95.9 mmol, Eq: 1.5). Reaction was stirred overnight at RT. Extraction with NaHCO₃ saturated aqueous solution and DCM.

5 Organic layer was dried on Na₂SO₄ and evaporated. Column on SiO₂ using MPLC ISCO with a gradient DCM/MeOH (Yield 68%). MS (ESI, *m/z*): 234.5 (MH⁺).


d) 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinonitrile



3-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridine 1-oxide (10.20 g, 43.7 mmol, Eq: 1.00)

10 was dissolved in DCM (163 mL). Trimethylsilanecarbonitrile (CAS 7677-24-9) (5.64 g, 7.11 mL, 56.9 mmol, Eq: 1.3) was then added dropwise followed by dimethylcarbamic chloride (7.06 g, 6.03 mL, 65.6 mmol, Eq: 1.5). The reaction mixture was stirred at room temperature over night. Saturated aqueous NaHCO₃ (20 mL) was added with stirring. The reaction mixture was poured into DCM and extracted with H₂O. The organic layers were 15 dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash chromatography on SiO₂ using MPLC ISCO with a gradient heptane in ethyl acetate (Yield 64%). MS (ESI, *m/z*): 243.5 (MH⁺).


e) 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid



20 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinonitrile (6.87 g, 28.4 mmol, Eq: 1.00) was dissolved in HCl 25% aqueous sol (170 mL, 1.4 mol, Eq: 50.0). Reaction was heated at 110°C. After 3 h reaction was complete. Reaction was cooled down to RT. HCl was neutralized using 6M NaOH aqueous solution followed by NaOH pellets. Then the pH was

adjusted to 1-2 with HCl 2M. The precipitate formed was filtered off to give title compound (Yield 99%). MS (ESI, *m/z*): 262.5 (MH⁺).


f) 3-cyclopropyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



5 To a solution of 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (50 mg, 191 µmol, Eq: 1.00) in dry DMF (1.5 mL) was added CDI (34.1 mg, 211 µmol, Eq: 1.1) and reaction stirred for 30 min at RT N'-hydroxycyclopropanecarboximidamide (CAS 51285-13-3) (211 µmol, Eq: 1.1) was added, stirred for 1 h at RT and after that overnight at 120°C. The reaction mixture was controlled by LC-MS. The reaction was directly purified by
10 preparative HPLC without any further work-up. MS (ESI, *m/z*): 326 (MH⁺).

Example 8

5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-(trifluoromethyl)-1,2,4-oxadiazole




15 The title compound was synthesized in analogy to Example 7f, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid and 2,2,2-trifluoro-N'-hydroxyacetimidamide (CAS 4314-35-6) as starting materials, and directly purified by preparative HPLC without any further work-up. MS (ESI, *m/z*): 354 (MH⁺).

Example 9


20 **5-cyclopropyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole**
a) 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide

- 47 -



To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)picolinonitrile (synthesis described previously as Example 1d) (390 mg, 1.82 mmol, Eq: 1.00) in EtOH (4 mL) was added hydroxylamine hydrochloride (126 mg, 1.82 mmol, Eq: 1.00) and triethylamine (184 mg, 5 254 µL, 1.82 mmol, Eq: 1.00). The reaction mixture was stirred at 70°C for 4 h and controlled by LC-MS which showed complete conversion to the desired product. The reaction mixture was diluted with ethyl acetate, poured into a separatory funnel, washed with water, and the organic phase dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 20 g SiO₂ column, eluent mixture of DCM and MeOH gave 10 418 mg of the desired product (Yield 88%). MS (ESI, *m/z*): 248.2 (MH⁺).

b) 5-cyclopropyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole




To a solution of cyclopropanecarboxylic acid (CAS 1759-53-1) (179 µmol, Eq: 1.05) in dry DMF (1.0 mL) was added CDI (28.9 mg, 179 µmol, Eq: 1.05) and the resulting 15 reaction mixture was stirred at RT for 45 min, followed by addition of 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide (42.0 mg, 170 µmol, Eq: 1.00). The reaction was then stirred at RT for 2 h and controlled by LC-MS which showed complete consumption of the starting material to produce the intermediate. The reaction was then heated at 130°C in a micro-wave for 45 min, controlled by LC-MS. The reaction was 20 directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 298.4 (MH⁺).

Example 10

5-tert-butyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole

- 48 -




The title compound was synthesized in analogy to Example 9b, using pivalic acid (CAS 75-98-9) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC without any work-up. MS 5 (ESI, *m/z*): 354 (MH⁺).

Example 11


2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole

a) 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(3-(hydroxymethyl)pentan-3-yl)picolinamide



10 To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid (previously described as Example 1e) (50 mg, 0.214 mmol, Eq: 1.00) in DCM (2 mL) was added 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride hydrate (CAS 3945-69-5) (69.5 mg, 0.236 mmol, Eq: 1.1). The reaction was stirred 30 min at RT. Then 2-amino-2-ethylbutan-1-ol (27.6 mg, 0.236 mmol, Eq: 1.1) (CAS 39884-49-6) was added and the 15 reaction stirred at RT overnight. LC-MS showed reaction was complete. Extraction with NaHCO₃ saturated aqueous solution and columning on SiO₂ with a gradient heptane / ethyl acetate gave 30 mg of the title compound (Yield 42%). MS (ESI, *m/z*): 333.3 (MH⁺).

b) 2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole




- 49 -

To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(3-(hydroxymethyl)pentan-3-yl)picolinamide (34 mg, 102 μ mol, Eq: 1.00) (carefully dried) in dry THF was added Burgess reagent (25.6 mg, 107 μ mol, Eq: 1.05). Reaction was stirred at RT under argon overnight. LC-MS showed reaction was complete. Evaporation of the solvent and extraction with NaHCO_3 saturated aqueous solution and ethyl acetate. Organic layer was dried on Na_2SO_4 and evaporated. Column on SiO_2 with a gradient heptane/ethyl acetate (Yield 62%). MS (ESI, m/z): 315.2 (MH $^+$).

Example 12


3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(methoxymethyl)-1,2,4-oxadiazole



The title compound was synthesized in a similar manner as Example 9b, using 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide with potassium carbonate (Eq: 1.0) and 2-methoxyacetyl chloride (CAS 38870-89-2) as starting materials and, directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 302.3 (MH $^+$).

Example 13


3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-ethyl-1,2,4-oxadiazole



The title compound was synthesized in a similar manner as Example 9b, using 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide with potassium carbonate (Eq: 1.0) and propionyl chloride (CAS 79-03-8) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 286.2 (MH $^+$).

Example 14

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole




The title compound was synthesized in a similar manner as Example 9b, using 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide with potassium carbonate (Eq: 1.0) and isobutyryl chloride (CAS 79-30-1) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 300.3 (MH⁺).

Example 15

3-cyclopropyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole


10 a) 3-bromo-4-(2,2,2-trifluoroethoxy)pyridine 1-oxide



To a solution of 3-bromo-4-(2,2,2-trifluoroethoxy)pyridine (previously described as Example 7a) (21 g, 67.3 mmol, Eq: 1.00) in DCM (400 mL) was added by portions *m*-CPBA (19.6 g, 87.4 mmol, Eq: 1.3). The reaction mixture was then stirred over the weekend at RT and monitored by LC-MS. Reaction mixture was poured into a separatory funnel and extracted with aqueous NaHCO₃ 1M. Aqueous phase was back-extracted with a mixture of ethyl acetate and organic phases were combined, dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 330 g SiO₂ column, eluent mixture of DCM and MeOH giving 16.2 g of the desired product (Yield 88%). MS (ESI, *m/z*): 272.3 (M).


b) 5-bromo-4-(2,2,2-trifluoroethoxy)picolinonitrile

- 51 -



3-bromo-4-(2,2,2-trifluoroethoxy)pyridine 1-oxide (21.5 g, 79 mmol, Eq: 1.00) was combined with DCM (344 mL). Trimethylsilanecarbonitrile (11.8 g, 14.8 mL, 119 mmol, Eq: 1.5) was then added dropwise followed by dimethylcarbamic chloride (12.7 g, 10.9 mL, 119 mmol, Eq: 1.5). The reaction mixture was stirred at room temperature over night. Saturated aqueous NaHCO_3 (20 mL) was added with stirring. The reaction mixture was poured into DCM and extracted with H_2O . The organic layers were dried over Na_2SO_4 and concentrated in vacuo. The crude material was purified by flash chromatography on SiO_2 using MPLC ISCO with a eluent gradient of heptane/ethyl acetate (Yield 27%). MS (ESI, m/z): 281.3 (M).


c) 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinonitrile



To a solution of 5-bromo-4-(2,2,2-trifluoroethoxy)picolinonitrile (587 mg, 2.09 mmol, Eq: 1.00) in dry toluene (10.4 mL) in a schlenk tube was added 3,3-difluoroazetidine hydrochloride (CAS 288315-03-7) (298 mg, 2.3 mmol, Eq: 1.1), Cs_2CO_3 (1.36 g, 4.18 mmol, Eq: 2.0), $\text{Pd}(\text{OAc})_2$ (46.9 mg, 209 μmol , Eq: 0.1) and BINAP (130 mg, 209 μmol , Eq: 0.1). The reaction mixture was heated to 120 °C and stirred for 1 h. Reaction mixture filtered over a pad of Celite, diluted with ethyl acetate, organic phase extracted with aqueous saturated NaHCO_3 , dried over Na_2SO_4 and evaporated down to dryness. The crude material was purified by flash chromatography (SiO_2 , 50 g, gradient ethyl acetate in heptane) giving 480 mg (Yield 78 %) of the desired compound. MS (ESI, m/z): 294.2 (MH^+).


d) 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinic acid

- 52 -



To a solution of 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinonitrile (680 mg, 2.32 mmol, Eq: 1.00) in EtOH (7.73 mL) in a schlenk tube was added KOH 4M aqueous solution (651 mg, 11.6 mmol, Eq: 5.0). The reaction mixture was heated to 105°C and stirred for 2 h. The reaction mixture was poured in a separatory funnel with a mixture of ethyl acetate and HCl 6.9M (2.69 mL, 18.6 mmol, Eq: 8.0) and water, extraction, the organic phase were collected, dried over Na₂SO₄ and evaporated down to give 397 mg of the desired product as an off-white solid (Yield 54%). MS (ESI, *m/z*): 311.2 (MH⁻).

e) 3-cyclopropyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-10 1,2,4-oxadiazole




In a 5 mL sealed vial, 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinic acid (100 mg, 320 μmol, Eq: 1.00) and CDI (54.5 mg, 336 μmol, Eq: 1.05) were combined with DMF (1.5 mL). The reaction mixture was stirred at room temp for 30 min. N¹-hydroxycyclopropanecarboximidamide (CAS 51285-13-3) (336 μmol, Eq: 1.05) was added and the mixture was stirred at room temp for 1 h. The reaction mixture was then heated to 120 °C for 4 h. The reaction mixture was poured into EtOAc and extracted with saturated NaHCO₃ aqueous solution. The organic layers were dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash chromatography (SiO₂, 10 g, with a gradient ethyl acetate in heptane) to give 33.6 mg of the title compound (Yield 27%). MS (ESI, *m/z*): 377.4 (MH⁺).

Example 16

5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole


- 53 -



The title compound was synthesized in analogy to Example 15e, using 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinic acid and N'-hydroxyacetimidamide (CAS 22059-22-9) as starting materials, and directly purified by flash chromatography (SiO_2 , 10 g, gradient ethyl acetate in heptane) giving 26 mg of desired compound (Yield 23%). MS (ESI, m/z): 351.2 (MH $^+$).

Example 17

3-tert-butyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole




10

The title compound was synthesized in analogy to Example 15e, using 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinic acid and N'-hydroxypivalimidamide (CAS 42956-75-2) as starting materials, and directly purified by flash chromatography (SiO_2 , 10 g, gradient ethyl acetate in heptane) giving 55 mg of desired compound (Yield 44%). MS (ESI, m/z): 393.3 (MH $^+$).

Example 18

[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]methanol




- 54 -

The title compound was synthesized in a similar maner as Example 9b, using 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide with potassium carbonate (Eq: 1.00) and 2-methoxyacetyl chloride (CAS 38870-89-2) as starting materials and after microwave heating was followed by addition of NaOH 4M aqueous solution (Eq: 5) 1.5) Reaction was stirred overnight at 80°C and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 288.1 (MH⁺).

Example 19

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(trifluoromethyl)-1,2,4-oxadiazole




10

The title compound was synthesized in a similar maner as Example 9b, using 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide with triethylamine (Eq: 1.1) and 2,2,2-trifluoroacetic anhydride (CAS 407-25-0) as starting materials in DCM and heated at 70°C with microwave. Solvent was removed in vacuo, residue redissolved in 15 DMF and directly purified by preparative HPLC to give the desired compound. MS (ESI, *m/z*): 326.2 (MH⁺).


Example 20

(4S)-4-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,5-dihydro-1,3-oxazole




20


The title compound was synthesized in analogy to Example 11, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid (previously described as Example 1e) and (S)-2-amino-3,3-dimethylbutan-1-ol (CAS 112245-13-3) as starting materials for the first step. MS (ESI, *m/z*): 315.2 (MH⁺).

Example 21**2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4-ethyl-4,5-dihydro-1,3-oxazole**

5 The title compound was synthesized in analogy to Example 11, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid (previously described as Example 1e) and 2-aminobutan-1-ol (CAS 96-20-8) as starting materials for the first step. MS (ESI, *m/z*): 287.2 (MH⁺).

Example 22**10 2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene**

The title compound was synthesized in analogy to Example 11, using 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid (previously described as Example 1e) and (1-aminocyclohexyl)methanol (CAS 4313-56-8) as starting materials for the first step. MS (ESI, *m/z*): 327.3 (MH⁺).


Example 23**15 1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol**

The title compound was synthesized in analogy to Example 9b, using 1-hydroxycyclopropanecarboxylic acid (CAS 17994-25-1) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 314.0 (MH⁺).

5

Example 24


3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 9b, using 1-methylcyclopropanecarboxylic acid (CAS 6914-76-7) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 312.1 (MH⁺).

Example 25

1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropane-1-carboxamide




The title compound was synthesized in analogy to Example 9b, using 1-carbamoylcyclopropanecarboxylic acid (CAS 6914-74-5) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 341.1 (MH⁺).

Example 26

- 57 -


2-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propan-2-ol



The title compound was synthesized in analogy to Example 9b, using 2-hydroxy-2-
 5 methylpropanoic acid (CAS 594-61-6) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-
 hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC
 without any work-up. MS (ESI, m/z): 316.2 (MH $^+$).

Example 27

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole




10

The title compound was synthesized in analogy to Example 11, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (previously described as Example 7e) and 2-amino-2-ethylbutan-1-ol (CAS 39884-49-6) as starting materials for the first step. MS (ESI, m/z): 343.2 (MH $^+$).

15

Example 28

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole




- 58 -

The title compound was synthesized in analogy to Example 9b, using 3-methyloxetane-3-carboxylic acid (CAS 28562-68-7) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 328.3 (MH $+$).

5

Example 29

5-(azetidin-3-yl)-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 9b, using 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (CAS 142253-55-2) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials followed by deprotection of the Boc group by evaporation of the DMF, crude redissolved in TFA. The reaction was stirred at RT for 30 min, volatiles were removed in vacuo and residue was redissolved in ethyl acetate. Organic phase was extracted with aqueous NaOH 1M, dried over Na₂SO₄ and evaporated down to dryness. Crude was purified by preparative HPLC. MS (ESI, m/z): 313.1 (MH $+$).

Example 30

2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole


20



The title compound was synthesized in a similar manner as Example 11, using 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinic acid (previously described as Example 15d) and 2-amino-2-ethylbutan-1-ol (CAS 39884-49-6) as starting materials for the first step. MS (ESI, m/z): 394.0 (MH $+$).

25


Example 31

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene

The title compound was synthesized in analogy to Example 11, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (previously described as Example 7e) and (1-aminocyclohexyl)methanol (CAS 4313-56-8) as starting materials for the first step. MS (ESI, *m/z*): 355.5 (MH⁺).

Example 32**5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole**


10 a) 3-bromo-4-(cyclopropylmethoxy)pyridine 1-oxide



In a 250 mL pear-shaped flask, 3-bromo-4-(cyclopropylmethoxy)pyridine, previously described as Example 1a, (3.7 g, 16.2 mmol, Eq: 1.00) was combined with DCM (81.1 mL) to give a colorless solution. *m*-CPBA (5.45 g, 24.3 mmol, Eq: 1.5) was added. The 15 reaction mixture was stirred at room temperature for 2 h. The reaction mixture was poured into 250 mL DCM and extracted with 1M NaHCO₃. The organic layers were dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash chromatography (SiO₂, 120 g, gradient MeOH in DCM) giving 3.39 g of the title compound as a white solid (Yield 85%). MS (ESI, *m/z*): 244.2 (M).

20 b) 5-bromo-4-(cyclopropylmethoxy)picolinonitrile

- 60 -




To a solution of 3-bromo-4-(cyclopropylmethoxy)pyridine 1-oxide (9.5 g, 38.9 mmol, Eq: 1.00) in dry DCM (160 mL) cooled down to 0°C and under argon atmosphere was slowly added TMS-CN (5.79 g, 7.83 mL, 58.4 mmol, Eq: 1.5) followed by addition of

5 dimethylcarbamoyl chloride (6.28 g, 5.37 mL, 58.4 mmol, Eq: 1.5). The reaction mixture was then stirred at RT overnight and monitored by LC-MS which showed complete consumption of the starting material. Addition of aqueous Na₂CO₃ 2M solution and mixture was stirred for 10 min, then poured into a separatory funnel, addition of water and extraction. Organic phase collected, dried over Na₂SO₄ and evaporated down to dryness.

10 Flash chromatography with a 120 g SiO₂ column, eluent mixture of heptane and ethyl acetate giving 3.52 g of the desired isomer (Yield 36%). MS (ESI, *m/z*): 253.4 (M).

c) 5-bromo-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide




To a solution of 5-bromo-4-(cyclopropylmethoxy)picolinonitrile (0.75 g, 2.96 mmol, Eq:

15 1.00) in EtOH (8 mL) was added hydroxylamine hydrochloride (309 mg, 4.44 mmol, Eq: 1.5) and triethylamine (450 mg, 620 μL, 4.44 mmol, Eq: 1.5). The reaction mixture was then stirred at 70°C for 45 min under microwave radiation and reaction monitored by TLC (eluent: ethyl acetate). Reaction mixture was poured into a separatory funnel, diluted with ethyl acetate, extracted with aqueous NaHCO₃ 1M. Organic phase dried over Na₂SO₄ and 20 evaporated down to dryness. Flash chromatography with a 50 g SiO₂ column, eluent mixture of heptane and ethyl acetate giving 482 mg of the desired product (Yield 57%). MS (ESI, *m/z*): 286.3 (M).


d) 3-(5-bromo-4-(cyclopropylmethoxy)pyridin-2-yl)-5-tert-butyl-1,2,4-oxadiazole

- 61 -



To a solution of 5-bromo-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide (2.1 g, 7.34 mmol, Eq: 1.00) in dry DMF (25 mL) under argon atmosphere at 0°C was added potassium carbonate (1.12 g, 8.07 mmol, Eq: 1.1) followed by slow addition of pivaloyl chloride (CAS 3282-30-2) (929 mg, 948 µL, 7.71 mmol, Eq: 1.05). The resulting reaction was stirred for 15 min at 0°C and then stirred for 30 min at RT, reaction was monitored by LC-MS. The reaction was then stirred at 130°C under microwave radiation for 30 min and controlled by LC-MS which showed complete conversion to the desired product. Removal of DMF in vacuo, residue redissolved in ethyl acetate and solution was poured into a separatory funnel. Extraction with aqueous NaHCO₃ 1M, organic phase dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 70 g SiO₂ column, eluent mixture of heptane and ethyl acetate giving 2.4 g of the desired product (Yield 93%). MS (ESI, *m/z*): 352.4 (M).

e) 5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole




To a solution of 3-(5-bromo-4-(cyclopropylmethoxy)pyridin-2-yl)-5-tert-butyl-1,2,4-oxadiazole (0.06 g, 170 µmol, Eq: 1.00) in dry toluene (1 mL) under argon atmosphere was added 3,3-difluoroazetidine hydrochloride (CAS 288315-03-7) (24.3 mg, 187 µmol, Eq: 1.1), Pd(OAc)₂ (3.82 mg, 17.0 µmol, Eq: 0.1), BINAP (10.6 mg, 17.0 µmol, Eq: 0.1) and Cs₂CO₃ (111 mg, 341 µmol, Eq: 2.0). The reaction mixture was stirred at 130°C for 60 min under microwave radiation and monitored by LC-MS. The reaction mixture was filtered over a pad of Celite, filtrate was evaporated down and dissolved in 1mL DMSO. Purification was done by preparative HPLC without any prior work-up. MS (ESI, *m/z*): 365.5 (MH⁺).

Example 33


5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole

a) 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide




To a solution of 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinonitrile, previously described as Example 7d, (1.62 g, 6.69 mmol, Eq: 1.00) in EtOH (13.0 mL) the following 5 was added hydroxylamine hydrochloride (465 mg, 6.69 mmol, Eq: 1.0) and triethylamine (677 mg, 932 μ L, 6.69 mmol, Eq: 1.0). The reaction was stirred for 3 h at 70°C and monitored with LC-MS. Another 0.5 Eq. of Hydroxylamine hydrochloride (232 mg) and triethylamine (465 μ L) were added as complete conversion had not taken place. The reaction was stirred for a further 3 h at 70°C. The reaction mixture was poured into a 10 separating funnel, ethyl acetate was added and the mixture was extracted with aqueous NaHCO₃ 1M. The organic phase was dried over Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash chromatography on SiO₂, 20 g, gradient ethyl acetate in heptane giving 650 mg of the title compound as a white powder (yield 35%). MS (ESI, *m/z*): 276.5 (MH⁺).

15 b) 5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole




To a solution of 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide (0.080 g, 291 μ mol, Eq: 1.00) in dry DMF (1.29 mL) under argon atmosphere was added K₂CO₃ (40.2 mg, 291 μ mol, Eq: 1.0) followed by pivaloyl chloride (CAS 3282-30-2) (35.0 mg, 35.8 μ L, 291 μ mol, Eq: 1.0). The reaction was stirred at RT for 45 min and controlled by LC-MS which showed complete conversion to the intermediate. The reaction mixture was stirred overnight at 120°C and controlled by LC-MS which showed complete conversion to the desired product. The reaction mixture was diluted with ethyl acetate, poured into a separatory funnel and extracted with water. The organic phase was dried over 20 Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography (SiO₂, 10 g, gradient ethyl acetate in heptane) giving 55 mg of the title 25 compound as a light yellow waxy solid (Yield 55%). MS (ESI, *m/z*): 342.5 (MH⁺).

Example 34**3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole**

5 The title compound was synthesized in analogy to Example 9b, using 1-methylcyclopropanecarboxylic acid (CAS 6914-76-7) and 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide, described as Example 33a, as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 340.4 (MH $+$).


10

Example 35**1-[6-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-4-(cyclopropylmethoxy)pyridin-3-yl]-6-oxa-1-azaspiro[3.3]heptane**

15 The title compound was synthesized in analogy to Example 32e, using 3-(5-bromo-4-(cyclopropylmethoxy)pyridin-2-yl)-5-tert-butyl-1,2,4-oxadiazole and 6-oxa-1-azaspiro[3.3]heptane hemioxalate (CAS 1359655-43-8) as starting materials, and purified by preparative HPLC. MS (ESI, m/z): 371.4 (MH $+$).

Example 36**3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole**

- 64 -




The title compound was synthesized in analogy to Example 33b, using 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide and isobutyryl chloride (CAS 79-30-1) as starting materials, and purified by flash chromatography. MS (ESI, m/z):

5 328.1 (MH $^+$).

Example 37

1-[3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol




10 The title compound was synthesized in analogy to Example 9b, using 1-hydroxycyclopropanecarboxylic acid (CAS 17994-25-1) and 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide (described as Example 33a) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, m/z): 342.1 (MH $^+$).

15

Example 38

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole




- 65 -

The title compound was synthesized in analogy to Example 9b, using 3-methyloxetane-3-carboxylic acid (CAS 28562-68-7) and 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide (described as Example 33a) as starting materials, and purified by purified by flash chromatography. MS (ESI, *m/z*): 356.5 (MH⁺).

5

Example 39

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole




5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide, described as Example 33a, (60 mg, 218 μ mol, Eq: 1.00) was combined with DCM (2.6 mL) and treated 10 with triethyl orthoformate (129 mg, 145 μ L, 872 μ mol, Eq: 4.0) under Nitrogen. The resulting solution was then treated with boron trifluoride etherate (3.09 mg, 2.76 μ L, 21.8 μ mol, Eq: 0.1) and allowed to stir for 2 h at RT. 0.5 more equivalents of triethyl 15 orthoformate (16.1 mg) and 0.1 equivalents of boron trifluoride etherate (0.773 mg) were added and the mixture left to stir overnight. The mixture was brought up to a basic pH with NaHCO_3 and extracted with DCM. The aqueous layer was then extracted with ethyl acetate two times. The organic layers were combined, dried and concentrated in vacuo. The crude material was purified by flash chromatography (SiO_2 , 10 g, gradient ethyl acetate in heptane) giving 48 mg of the title compound as a white solid (Yield 77%). MS (ESI, *m/z*): 286.4 (MH⁺).


20

Example 40


3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 7f, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid and N'-hydroxypivalimidamide (CAS 42956-75-2) as 25 starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 342.5 (MH⁺).

Example 41**2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5,5-dimethyl-4H-1,3-oxazole**

The title compound was synthesized in a similar manner as Example 11, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (previously described as Example 7e) and 1-amino-2-methylpropan-2-ol (CAS 2854-16-2) as starting materials for the first step. The second step differs as follows: To a solution of 5-cyclopropyl-N-(2-hydroxy-2-methylpropyl)-4-(2,2,2-trifluoroethoxy)picolinamide (60 mg, 0.181 mmol, Eq: 1.00) in DCM (900 μ L) was added methanesulfonic acid (59 μ L, 0.9 mmol, Eq: 5.0). Reaction was heated at 40°C 2 h. LC-MS showed reaction was complete. Extraction with DCM/NaHCO₃ saturated aqueous solution. Organic layer was dried on MgSO₄ and evaporated. Column on SiO₂ with a gradient heptane/ethyl acetate. MS (ESI, *m/z*): 315.5 (MH⁺) to give 5.9 mg of the title compound as colorless viscous oil.


Example 42**15 5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-propan-2-yl-1,2,4-oxadiazole**

The title compound was synthesized in analogy to Example 7f, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid and N'-hydroxyisobutyrimidamide (CAS 35613-84-4) as starting materials, and directly purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 328.4 (MH⁺).

Example 43**5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-methylsulfonylpyridin-2-yl]-1,2,4-oxadiazole**


a) 5-tert-butyl-3-(4-(cyclopropylmethoxy)-5-(methylthio)pyridin-2-yl)-1,2,4-oxadiazole

- 67 -



To a solution of 3-(5-bromo-4-(cyclopropylmethoxy)pyridin-2-yl)-5-tert-butyl-1,2,4-oxadiazole, previously described as Example 32d, (0.08 g, 227 μ mol, Eq: 1.00) in dry DMF (1.5 mL) under argon atmosphere was added methanethiol, sodium salt (CAS 5188-07-8) (19.4 mg, 273 μ mol, Eq: 1.2) and the resulting reaction mixture was stirred at 100°C overnight and controlled by TLC. Reaction mixture poured into a separatory funnel, dilution with ethylacetate, extraction with aqueous NaHCO₃ 1M. The aqueous phase was back-extracted with ethyl acetate, organic phase combined, dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 10 g SiO₂ column, eluent mixture of heptane and ethyl acetate gave 49 mg of the desired product (Yield 67%). MS (ESI, *m/z*): 319.9 (MH⁺).

b) 5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-methylsulfonylpyridin-2-yl]-1,2,4-oxadiazole




To a solution of 5-tert-butyl-3-(4-(cyclopropylmethoxy)-5-(methylthio)pyridin-2-yl)-1,2,4-oxadiazole (0.045 g, 141 μ mol, Eq: 1.00) in DCM (1 mL) was added *m*-CPBA (63.1 mg, 282 μ mol, Eq: 2.0). The reaction mixture was stirred at RT overnight and controlled by LC-MS. Only partial conversion to the sulfone and no more starting material but major product is the sulfoxide. Addition of *m*-CPBA (12.2 mg, 70.4 μ mol, Eq: 0.5) to the reaction mixture was stirred at RT for 2 h, control by LC-MS showed change in conversion but not total. The reaction was stopped anyway. Evaporation of the volatiles and residue was redissolved in DMSO for purification by preparative HPLC without any work-up giving 18.3 mg of the desired product (Yield 37%). MS (ESI, *m/z*): 352.5 (MH⁺).

Example 44

5-tert-butyl-3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole


a) 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide

- 68 -



To a solution of 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinonitrile, previously described as Example 15c, (1 g, 3.41 mmol, Eq: 1.00) in EtOH (16.6 mL) was added hydroxylamine hydrochloride (261 mg, 156 μ L, 3.75 mmol, Eq: 1.1) and 5 triethylamine (380 mg, 524 μ L, 3.75 mmol, Eq: 1.1). The reaction mixture was heated up to 70°C and left for half an hour. LC-MS showed the reaction was complete. The reaction mixture was poured into a separatory funnel, ethyl acetate was added and the mixture was extracted with aqueous saturated NaHCO_3 1M. The organic phase was dried over Na_2SO_4 and evaporated down to dryness to give 1.09 g of the desired compound as a white powder 10 (yield 98%). MS (ESI, m/z): 327.2 (MH $^+$).


b) 5-tert-butyl-3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



To a solution of 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide (0.08 g, 245 μ mol, Eq: 1.00) in dry DMF (1.09 mL) 15 under argon atmosphere was added K_2CO_3 (37.3 mg, 270 μ mol, Eq: 1.1) followed by pivaloyl chloride (CAS 3282-30-2) (32.5 mg, 33.2 μ L, 270 μ mol, Eq: 1.1). The reaction was stirred at RT for 45 min and controlled by LC-MS which showed complete conversion to the intermediate. The reaction mixture was stirred overnight at 120°C and controlled by 20 LC-MS which showed complete conversion to the desired product. The reaction mixture was diluted with ethyl acetate, poured into a separatory funnel and extracted with water. The organic phase was dried over Na_2SO_4 and evaporated down to dryness. The crude material was purified by flash chromatography (SiO_2 , gradient ethyl acetate in heptane) giving 44 mg of the title compound as a white powder (Yield 45%). MS (ESI, m/z): 393.1 25 (MH $^+$).

Example 45


3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 44b, using 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide and isobutyryl chloride (CAS 79-30-1) as starting materials, and purified by flash chromatography. MS (ESI, m/z): 379.1 (MH $^+$).

Example 46


1-[3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol



To a solution of 1-hydroxycyclopropanecarboxylic acid (CAS 17994-25-1) (27.5 mg, 270 μ mol, Eq: 1.1) in DMF (1.44 mL) was added CDI (43.7 mg, 270 μ mol, Eq: 1.1) and the resulting reaction mixture was stirred at RT for 45min, followed by the addition of 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide, previously described as Example 44a, (80 mg, 245 μ mol, Eq: 1.00). The reaction was then stirred at RT for 2 h and monitored by LC-MS which showed complete consumption of the starting material to form the intermediate. The reaction mixture was then heated to 130°C and left to stir overnight. The reaction was diluted with ethyl acetate and extracted with water. The organic layers were dried over Na_2SO_4 and concentrated in vacuo. The crude material was purified by flash chromatography (SiO_2 , 10 g, gradient ethyl acetate in heptane) giving 41.7 mg of the title compound as a white powder (Yield 43%). MS (ESI, m/z): 393.4 (MH $^+$).

Example 47

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 46, using 3-methyloxetane-3-carboxylic acid (CAS 28562-68-7) and 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide as starting materials, and purified by purified by flash chromatography. MS (ESI, m/z): 407.5 (MH $^+$).

Example 48

5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole


a) 2,4-dichloro-5-cyclopropylpyridine



To a solution of 5-bromo-2,4-dichloropyridine (CAS 849937-96-8) (22.95 g, 96.1 mmol, Eq: 1.00) in Toluene (352 mL) and Water (48.0 mL) was added Pd(OAc) $_2$ (431 mg, 1.92 mmol, Eq: 0.02), butyldi-1-adamantylphosphine (1.03 g, 2.88 mmol, Eq: 0.03), potassium cyclopropyltrifluoroborate (CAS 1065010-87-8) (14.9 g, 101 mmol, Eq: 1.05) and Cs $_2$ CO $_3$ (62.6 g, 192 mmol, Eq: 2.0). The resulting reaction mixture was stirred at 110°C overnight and controlled by TLC. The reaction was found to be only partially complete so 0.5 more equivalents (7.5 g) of potassium cyclopropyltrifluororate were added (3 times). Reaction mixture concentrated in vacuo then diluted with ethyl acetate and the solution poured into a separatory funnel. Extraction with aqueous saturated NaHCO $_3$, organic phase dried over NaSO $_4$ and evaporated down to dryness. Flash chromatography with a 330 g SiO $_2$ column, eluent mixture of heptane and ethyl acetate giving 7.39 g of the desired product (Yield 40%). MS (ESI, m/z): 188.2 (M).

b) 4-chloro-5-cyclopropylpicolinonitrile

- 71 -




To a solution of 2,4-dichloro-5-cyclopropylpyridine (7.35 g, 39.1 mmol, Eq: 1.00) dissolved in dry DMF (130 mL), dppf (1.73 g, 3.13 mmol, Eq: 0.08) was added followed by dicyanozinc (2.75 g, 23.5 mmol, Eq: 0.6) and Pd_2dba_3 (1.95 mmol, Eq: 0.05). Reaction 5 was stirred at 100°C for 2 h, controlled by TLC. Reaction mixture filtered on a pad of Celite, filtrate diluted with ethyl acetate, extraction with water, aqueous phase back-extracted with ethyl acetate, organic phase dried over Na_2SO_4 and concentrated in vacuo. Purification with a 330 g SiO_2 column, eluent mixture of Heptane and EtOAc giving 6.82 g of the title compound as a yellow solid (Yield 97%). MS (ESI, m/z): 179.2 (MH $^+$).

10 c) 4-chloro-5-cyclopropyl-N'-hydroxypicolinimidamide



To a solution of 4-chloro-5-cyclopropylpicolinonitrile (3.2 g, 17.9 mmol, Eq: 1.00) in EtOH (120 mL) was added hydroxylamine hydrochloride (1.87 g, 26.9 mmol, Eq: 1.5) and triethylamine (5 mL, 35.8 mmol, Eq: 2.0). The reaction was heated at 90°C and monitored 15 with LC-MS. The reaction mixture was poured into a separating funnel, diluted with DCM and the mixture extracted with aqueous NaHCO_3 saturated solution. The organic phase was dried over Na_2SO_4 and concentrated in vacuo to give a white crystalline solid (Yield 96%). MS (ESI, m/z): 212.5 (MH $^+$).

d) 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole




20

To a solution of 4-chloro-5-cyclopropyl-N'-hydroxypicolinimidamide (3.64 g, 17.2 mmol, Eq: 1.00) in dry DMF (115 mL) was added pivaloyl chloride (CAS 3282-30-2) (2.7 g, 2.75 mL, 22.4 mmol, Eq: 1.3) and triethylamine (4.79 mL, 34.4 mmol, Eq: 2.0). The reaction was stirred at RT 30 min. LC-MS showed formation of the intermediate. Reaction mixture 25 was then heated at 110°C overnight. Solvent was partially evaporated and the crude extracted with ethyl acetate and NaHCO_3 aqueous saturated solution. Organic layer was

- 72 -

dried on Na_2SO_4 and evaporated. Column on SiO_2 column using MPLC ISCO with a gradient ethyl acetate in heptane gave the title product as yellow viscous oil (Yield 77%).
MS (ESI, m/z): 278.6 (MH $^+$).


e) 5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-
5 oxadiazole



To a solution of 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole (0.05 g, 180 μmol , Eq: 1.00) in dry DMF (1.5 mL) was added (S)-1,1,1-trifluoropropan-2-ol (CAS 3539-97-7) (30.8 mg, 270 μmol , Eq: 1.5) followed by NaH (10.8 mg, 270 μmol , Eq: 10 1.5). The reaction mixture was stirred at RT for 15 min, then stirred under microwave radiation for 30 min at 100°C and monitored by LC-MS. The reaction mixture was quenched with water and directly purified by preparative HPLC without any work-up giving 44.2 mg of the desired product (Yield 69%). MS (ESI, m/z): 356.5 (MH $^+$).

Example 49

15 **5-tert-butyl-3-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole**




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (R)-1,1,1-trifluoropropan-2-ol (75% in TBME) (CAS 17628-73-8) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 356.5 (MH $^+$).

Example 50

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole

- 73 -




The title compound was synthesized in analogy to Example 46, using 1-methylcyclopropanecarboxylic acid (CAS 6914-76-7) and 5-(3,3-difluoroazetidin-1-yl)-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide as starting materials, and purified by 5 purified by flash chromatography. MS (ESI, *m/z*): 391.1 (MH⁺).

Example 51

3-tert-butyl-5-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole

a) 4-chloro-3-cyclopropylpyridine


10



To a solution of 3-bromo-4-chloropyridine (7.1 g, 36.9 mmol, Eq: 1.00) in toluene/water (153 mL/ 18 mL) was added Potassium Cyclopropyltrifluoroborate (CAS 1065010-87-8) (8.41 g, 38.7 mmol, Eq: 1.05), palladium (II) acetate (331 mg, 1.48 mmol, Eq: 0.04), cesium carbonate (30.1 g, 92.2 mmol, Eq: 2.5) and Butyldi-1-Adamantylphosphine (661 mg, 1.84 mmol, Eq: 0.05). Reaction was stirred at 115°C overnight under argon. LC-MS 15 showed product. Extraction with water/ethyl acetate (3 times). Organic layer was dried on MgSO₄ and evaporated. Column on SiO₂ with a gradient heptane/ethyl acetate gave 3.8 g of the desired compound as a yellow oil (Yield 67%). MS (ESI, *m/z*): 154.0 (MH⁺).

b) 4-Chloro-5-cyclopropyl-pyridine-2-carboxylic acid


20



To a solution of N,N-Dimethylethanolamine (2.18 g, 2.46 mL, 24.4 mmol, Eq: 2.5) in Hexane at -15°C under argon was slowly added BuLi 1.6M in Hexane (30.5 mL, 48.8 mmol, Eq: 5.0). The reaction was stirred at -15°C during 20 min. The reaction was cooled


down to -78°C before addition of 4-chloro-3-cyclopropylpyridine (1.5 g, 9.77 mmol, Eq: 1.0). Reaction was stirred 1 h at -78°C before pellets of dry ice addition. The reaction was slowly allowed to reach -20°C. LC-MS confirmed product formation. Reaction was quenched with water and stirred 5 min. Extraction with HCl 4M aqueous solution and 5 ethyl acetate (3 times). Organic layer was dried on MgSO₄ and evaporated to give yellow oil. Diethyl ether was poured on the crude, giving a white suspension, and placed in the fridge. Filtration and washed with ether. Mother liquor was concentrated and again ether was added. Precipitate was filtered and dried under high vaccum giving 850 mg of title compound as white powder (Yield 44%). MS (ESI, *m/z*): 196.0 (MH-).

10 c) 3-tert-butyl-5-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole



To a solution of 4-chloro-5-cyclopropylpicolinic acid (300 mg, 1.52 mmol, Eq: 1.00) in dry DMF (6 mL) was added CDI (369 mg, 2.28 mmol, Eq: 1.5) and reaction stirred for 30 min at RT. N'-hydroxypivalimidamide (CAS 42956-75-2) (265 mg, 2.28 mmol, Eq: 1.5) 15 was then added, stirred for 1 h at RT and heated to 100°C over night. The reaction mixture was controlled by LC-MS. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate. The extraction was accomplished with 1M NaHCO₃, dried over Na₂SO₄ and concentrated. The crude material was purified by flash chromatography (SiO₂, 10 g, eluent: heptane/ethyl acetate) giving 100 mg of the title compound as light yellow 20 liquid (Yield 23%). MS (ESI, *m/z*): 278.4 (MH+).

d) 3-tert-butyl-5-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole




To a solution of 3-tert-butyl-5-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole (48 25 mg, 173 µmol, Eq: 1.00) in dry DMF (100 mL) were added (R)-1,1,1-trifluoropropan-2-ol (84.5 mg, 518 µmol, Eq: 3.0) (CAS 17628-73-8) and NaH (20.7 mg, 518 µmol, Eq: 3.0) and reaction stirred at RT for 30 min. The reaction mixture was then heated to 100°C for

30 min in the microwave. The reaction was directly purified by preparative HPLC without any work-up giving the title compound as a white solid. MS (ESI, *m/z*): 356.3 (MH⁺).

Example 52


5 **3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole**



The title compound was synthesized in analogy to Example 51d, using 3-tert-butyl-5-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (S)-1,1,1-trifluoropropan-2-ol (CAS 3539-97-7) as starting materials, and purified by preparative HPLC without any 10 work-up. MS (ESI, *m/z*): 356.4 (MH⁺).

Example 53

5 **5-tert-butyl-3-[5-cyclopropyl-4-[(4-fluorophenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole**




15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (4-fluorophenyl)methanol (CAS 459-56-3) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 368.6 (MH⁺).

Example 54

20 **5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole**


- 76 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and oxetan-3-ol (CAS 7748-36-9) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 5 316.5 (MH⁺).

Example 55


5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole



10 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (3-methyloxetan-3-yl)methanol (CAS 3143-02-0) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 344.5 (MH⁺).

Example 56

15 5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (tetrahydrofuran-2-yl)methanol (CAS 97-99-4) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 344.6 (MH⁺).

Example 57

5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole


- 77 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (S)-(1-methylpyrrolidin-2-yl)methanol (CAS 34381-71-0) as starting materials, and purified by preparative HPLC 5 without any work-up. MS (ESI, m/z): 357.2 (MH $^+$).

Example 58


5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and oxetan-2-ylmethanol (CAS 61266-10-4) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 330.5 (MH $^+$).

Example 59

5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-methylpyrrolidin-3-ol (CAS 13220-33-2) as starting materials, and purified by preparative HPLC without any work-up. 20 MS (ESI, m/z): 343.5 (MH $^+$).

Example 60

3-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]oxetan-3-amine

a) N-(3-(3-(5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl)-1,2,4-oxadiazol-5-yl)oxetan-3-yl)-2,2,2-trifluoroacetamide




5

The title compound was synthesized in analogy to Example 9b, using 3-(2,2,2-trifluoroacetamido)oxetane-3-carboxylic acid (CAS 1392072-19-3) and 5-cyclopropyl-4-(cyclopropylmethoxy)-N'-hydroxypicolinimidamide as starting materials. DMF was evaporated, residue redissolved in ethyl acetate and poured into a separatory funnel,

10 extraction with aqueous NaHCO₃ 1M, organic phase dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with SiO₂ column, eluent mixture of heptane and ethyl acetate. MS (ESI, *m/z*): 425.2 (MH⁺).

b) 3-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]oxetan-3-amine




15

To a solution of N-(3-(3-(5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl)-1,2,4-oxadiazol-5-yl)oxetan-3-yl)-2,2,2-trifluoroacetamide (0.06 g, 141 μmol, Eq: 1.00) in ammonia 7N in MeOH (1.01 mL, 7.07 mmol, Eq: 50.0) was stirred at 100°C for 30 min under microwave radiation and reaction was monitored by LC-MS. When the reaction was 20 completed, volatiles were removed in vacuo and the residue was redissolved in DMF. Purification was done by preparative HPLC without any work-up procedure and gave 9 mg of the desired product. MS (ESI, *m/z*): 329.4 (MH⁺).

Example 61

5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole


- 79 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 4-fluorophenol (CAS 371-41-5) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 5 354.5 (MH⁺).

Example 62


5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and tetrahydrofuran-3-ol (CAS 453-20-3) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 10 330.5 (MH⁺).

Example 63

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole



15

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and tetrahydro-2H-pyran-4-ol (CAS 2081-44-9) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 344.5(MH⁺).


20

Example 64

- 80 -


2-(5-tert-butyl-1*H*-imidazol-2-yl)-5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine

a) 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinimidamide



5 To a solution of ammonium chloride (47.4 mg, 887 μ mol, Eq: 2) in toluene (0.56 mL) was added at 0°C for 10 minutes trimethylaluminum (443 μ L, 887 μ mol, Eq: 2.0). Reaction was then brought at RT for 20 minutes. 5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinonitrile (130 mg, 443 μ mol, Eq: 1.00), previously described as Example 15c, dissolved in toluene was then added and the reaction mixture heated up to 10 80°C and stirred for 1 h. The reaction mixture was then cooled down to RT, quenched with water and poured into a DCM/silica slurry. This was then filtered and washed through with methanol to give 250 mg of a yellow solid. The crude material was purified by flash chromatography on SiO_2 , 10 g, gradient methanol in DCM giving 21 mg of the title compound as light yellow powder (Yield 15%). MS (ESI, m/z): 311.4 (MH $^+$).

15 b) 2-(5-tert-butyl-1*H*-imidazol-2-yl)-5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine




5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)picolinimidamide (20 mg, 64.5 μ mol, Eq: 1.00), 1-bromo-3,3-dimethylbutan-2-one (24.2 mg, 18.2 μ L, 135 μ mol, Eq: 2.1) 20 and DBU (49.1 mg, 48.6 μ L, 322 μ mol, Eq: 5.0) were combined with Ethanol (0.77 mL). The reaction mixture was heated up to 115°C and stirred overnight. The crude material was purified by preparative HPLC giving 5 mg of the title compound as white powder (Yield 19%). MS (ESI, m/z): 391.5 (MH $^+$).

Example 65


25 **5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,3-oxazole**

a) 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(2-hydroxy-3,3-dimethylbutyl)picolinamide




To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)picolinic acid, previously described as Example 1e, (200 mg, 0.857 mmol, Eq: 1.00) in 8.5 mL DCM was added HATU (158 mg, 1.03 mmol, Eq: 1.2) and DIPEA (449 μ L, 2.57 mmol, Eq: 3.0). Reaction was stirred 5 15 min at 40°C, then 1-amino-3,3-dimethylbutan-2-ol hydrochloride (158 mg, 1.03 mmol, Eq: 1.2) (CAS 1438-15-9) was added. Reaction was stirred 2 h at 40°C. Extraction with DCM/NaHCO₃ saturated aqueous solution. Organic layer was dried on sodium sulfate and evaporated. Column on SiO₂ with a gradient heptane/ethyl acetate gave 126 mg of the title compound as colorless viscous oil (Yield 44%). MS (ESI, *m/z*): 333.5 (MH⁺).

10 b) 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(3,3-dimethyl-2-oxobutyl)picolinamide




To a solution of 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(2-hydroxy-3,3-dimethylbutyl)picolinamide (125 mg, 0.376 mmol, Eq: 1.00) in DCM (3.8 mL) was added Dess-Martin periodinane (181 mg, 0.414 mmol, Eq: 1.1) and the reaction was stirred 15 overnight at RT. LC-MS showed reaction was complete. Sodium thiosulfate solution was added to the crude and stirred for 10 min before extraction with NaHCO₃ saturated aqueous solution and DCM. Column on SiO₂ with a gradient heptane/ethyl acetate gave 116 mg of the title compound as white waxy solid (Yield 93%). MS (ESI, *m/z*): 331.5 (MH⁺).

20 c) 5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,3-oxazole



Hexachloroethane was dissolved in anhydrous acetonitrile. Then 5-cyclopropyl-4-(cyclopropylmethoxy)-N-(3,3-dimethyl-2-oxobutyl)picolinamide was dissolved in Acetonitrile and added. The reaction mixture was cooled to 0°C and triethylamine followed by triphenylphosphine were added. The ice bath was removed and the reaction 5 mixture was stirred for 2 hours. LC-MS showed some SM left. Another 3 Eq. hexachloroethane, triethylamine and finally triphenylphosphine were added at 0°C. Acetonitrile was evaporated and the crude extracted with DCM/ brine 3 times. Organic layer was dried on Na₂SO₄ and evaporated. Column on SiO₂ with a gradient heptane/ethyl acetate to give 14 mg of the title compound (Yield 60%). MS (ESI, *m/z*): 313.5 (MH⁺).

10

Example 66**2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1*H*-imidazol-5-one**


5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid, previously described as Example 7e, 15 (100 mg, 383 µmol, Eq: 1.00) in 1,2-Dichloroethane (1.91 mL) had thionyl chloride (68.3 mg, 41.9 µL, 574 µmol, Eq: 1.5) added to it. The reaction mixture was heated up to 90°C and left to reflux for 3h. The reaction mixture was concentrated in vacuo. Product was used immediately in the next step and dissolved in THF (526 µL). A mixture of 2-amino-2,3-dimethylbutanamide (46.6 mg, 358 µmol, Eq: 1.00) and triethylamine (36.2 mg, 49.8 µL, 358 µmol, Eq: 1.0) in 130 µL of tetrahydrofuran was added and the reaction stirred at 20 4 h at RT. The reaction mixture was poured into water, extracted with ethyl acetate and the organic layers combined, dried, and concentrated in vacuo to give a solid which was used immediately in the next step and dissolved in THF (536 µL). This was added to a solution of potassium hydroxide (40.3 mg, 718 µmol, Eq: 2.0) and water (15 µL) and the reaction 25 was refluxed for 2 hours. The mixture was poured into water and extracted with ethyl acetate. The organic layers were combined before being dried on Na₂SO₄ and concentrated in vacuo. The crude material was purified by flash chromatography (SiO₂, 10 g, gradient ethyl acetate in heptane) giving 43 mg of the title compound as a white solid (Yield 34%). MS (ESI, *m/z*): 356.1 (MH⁺).

30

Example 67**5-tert-butyl-3-[5-methylsulfonyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole**


- 83 -

a) 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-(methylsulfonyl)pyridin-4-ol




To a solution of 5-tert-butyl-3-(4-(cyclopropylmethoxy)-5-(methylsulfonyl)pyridin-2-yl)-1,2,4-oxadiazole, described as Example 43, (330 mg, 939 μ mol, Eq: 1.00) in dry DCM (5 ml) under an argon atmosphere was added BBr_3 1M solution in DCM (1.88 mL, 1.88 mmol, Eq: 2.0). The reaction mixture was stirred at RT overnight and monitored by LC-MS until complete conversion. The reaction mixture was quenched by addition of water, stirred for 10 min and the mixture was then poured into a separatory funnel and pH was adjusted to 7 and extracted with DCM and then ethyl acetate. All the organic layers were dried over Na_2SO_4 and evaporated down to dryness giving 140 mg of the title compound as white solid (Yield 50%). MS (ESI, m/z): 296.4 (MH $^-$).

b) 5-tert-butyl-3-[5-methylsulfonyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



To a solution of 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-(methylsulfonyl)pyridin-4-ol (40 mg, 135 μ mol, Eq: 1.00) in DMF (1 mL) was added Cs_2CO_3 (65.7 mg, 202 μ mol, Eq: 1.5) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (CAS 6226-25-1) (62.4 mg, 38.8 μ L, 269 μ mol, Eq: 2.0). Reaction was heated at 90°C during 1.5 h in the microwave and purified by preparative HPLC without any work-up. MS (ESI, m/z): 380.5 (MH $^+$).


Example 68

20 2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-ethyl-4-methyl-1*H*-imidazol-5-one

The title compound was synthesized in a similar manner as Example 66, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (Eq: 1.0), previously described as Example 7e, with CDI (Eq: 1.1), DIPEA (Eq: 2.2) and 1-amino-2-methyl-1-oxobutan-2-aminium chloride (CAS 18305-22-1) as starting materials for the amide coupling step. MS 5 (ESI, *m/z*): 342.1 (MH⁺).

Example 69

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-(2-methylpropyl)-1*H*-imidazol-5-one




10 The title compound was synthesized in analogy to Example 68, using 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (Eq: 1.0), previously described as Example 7e, with CDI (Eq: 1.1), DIPEA (Eq: 2.2) and 2-amino-2,4-dimethylpentanamide (CAS 113509-60-7) as starting materials for the amide coupling step. MS (ESI, *m/z*): 370.5 (MH⁺).

Example 70

15 **5-tert-butyl-3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole**


a) 2,5-dichloro-4-(2,2,2-trifluoroethoxy)pyridine



To a solution of 2,5-dichloropyridin-4-ol (CAS 847664-65-7) (5 g, 30.5 mmol, Eq: 1.00) in DMF (51 mL) was added cesium carbonate (14.9 g, 45.7 mmol, Eq: 1.5) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (6.59 mL, 45.7 mmol, Eq: 1.5). Reaction was heated at 90°C overnight. Reaction was filtered to remove Cs₂CO₃ (cake washed with ethyl acetate) and solvent evaporated. Extraction of the crude using ethyl acetate/water. Organic layer was dried on Na₂SO₄ and evaporated. Column on SiO₂ using MPLC Isco with a gradient heptane/ethyl acetate gave 6.64 g of title compound as off-white solid (Yield 20 88%). MS (ESI, *m/z*): 246.3 (MH⁺).


25 b) 5-chloro-4-(2,2,2-trifluoroethoxy)picolinonitrile

- 85 -



2,5-dichloro-4-(2,2,2-trifluoroethoxy)pyridine (4 g, 16.3 mmol, Eq: 1.00), Dicyanozinc (2.1 g, 17.9 mmol, Eq: 1.1), 1,1'-bis(diphenylphosphino)ferrocene (721 mg, 1.3 mmol, Eq: 0.08) and $\text{Pd}_2(\text{dba})_3$ (744 mg, 0.813 mmol, Eq: 0.05) were combined in DMF and the reaction heated at 100°C 2 days. Evaporation of the solvent, extraction with ethyl acetate / NaHCO_3 saturated aqueous solution Organic layer dried on sodium sulfate and evaporated. Column on SiO_2 with MPLC Isco with a gradient heptane/ethyl acetate gave 2.1 g of title compound as white solid (Yield 54%). MS (ESI, m/z): 237.3 (MH $^+$).


c) 5-chloro-N-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide



10

To a solution of 5-chloro-4-(2,2,2-trifluoroethoxy)picolinonitrile (200 mg, 0.845 mmol, Eq: 1.00) in EtOH (5.6 mL) was added hydroxylamine hydrochloride (65 mg, 0.93 mmol, Eq: 1.1) and triethylamine (128 mg, 177 μL , 1.27 mmol, Eq: 1.5). The reaction was heated with microwave 30 min at 80°C and monitored with LC-MS. The reaction mixture was poured into a separating funnel, DCM was added and the mixture was extracted with aqueous NaHCO_3 saturated solution. The organic phase was dried over Na_2SO_4 and concentrated in vacuo to give 223 mg of title compound as white powder (Yield 97%). MS (ESI, m/z): 270.4 (MH $^+$).

d) 5-tert-butyl-3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



20


To a solution of 5-chloro-N-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide (0.1 g, 371 μmol , Eq: 1.00) in dry DMF (2.5 mL) under argon atmosphere was added DIPEA (130 μL , 742 μmol , Eq: 2.0) followed by pivaloyl chloride (CAS 3282-30-2) (53.7 mg, 54.8 μL , 445

μmol, Eq: 1.2). The reaction was stirred at RT for 45 min and controlled by LC-MS which showed complete conversion to the intermediate. The reaction mixture was heated with microwave 30 min at 120°C and controlled by LC-MS which showed complete conversion to the desired product. The solvent was evaporated and the crude diluted with ethyl acetate, 5 poured into a separatory funnel and extracted with NaHCO₃ aqueous saturated solution. The organic phase was dried over Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography (SiO₂, 20 g, gradient ethyl acetate in heptane) gave 92 mg of the title compound as white powder (Yield 73%). MS (ESI, *m/z*): 336.4 (MH⁺).

10

Example 71


3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-cyclopropyl-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 70d, using 5-chloro-N-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide and cyclopropanecarboxylic acid (CAS 15 1759-53-1) as starting materials, with HATU (Eq: 1.2) and DIPEA (Eq: 2.0), and heated with microwave 30 min at 120°C. MS (ESI, *m/z*): 320.4 (MH⁺).

Example 72

5-cyclopropyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole




20 The title compound was synthesized in analogy to Example 33b, using 5-cyclopropyl-N'-hydroxy-4-(2,2,2-trifluoroethoxy)picolinimidamide and cyclopropanecarbonyl chloride (CAS 4023-34-1) as starting materials, and purified by purified by flash chromatography. MS (ESI, *m/z*): 326.6 (MH⁺).

Example 73

25 1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]pyrrolidin-3-ol


- 87 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-pyrrolidinol (CAS 40499-83-0) (Eq: 2.0) as starting materials in NMP with K_2CO_3 (Eq: 3.0), heated 1h30 at 200°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 329.6 (MH+).

Example 74

5-tert-butyl-3-[5-cyclopropyl-4-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole




10


The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3,3,4,4-tetrafluoropyrrolidine hydrochloride (CAS 1810-13-5) (Eq: 2.0) as starting materials in Sulfolane with K_2CO_3 (Eq: 3.0), heated 2 h at 180°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 385.6 (MH+).

Example 75

5-tert-butyl-3-[5-cyclopropyl-4-(4-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole




20 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 4-methylsulfonylphenol (CAS 14763-60-1) (Eq: 1.2) as starting materials in NMP, heated 1 h at 180°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 414.6 (MH+).

Example 76**7-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-7-azaspiro[3.4]octane**

5 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 2-oxa-6-azaspiro[3.4]octane (CAS 220290-68-6) (Eq: 2.0) as starting materials in NMP with K_2CO_3 (Eq: 3.0), heated 1h30 at 200°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 355.6 (MH $^+$).


10

Example 77**5-tert-butyl-3-[5-cyclopropyl-4-(3,3-difluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole**

15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3,3-difluoropyrrolidine hydrochloride (CAS 163457-23-6) (Eq: 2.0) as starting materials in Sulfolane with K_2CO_3 (Eq: 3.0), heated 30 min at 220°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, m/z): 349.6 (MH $^+$).

Example 78

20 **4-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]morpholine**




- 89 -

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and morpholine (CAS 110-91-8) (Eq: 1.2) as starting materials in DMSO with CsF (Eq: 1) and triethylamine (Eq: 2.0), heated 24 h at 150°C, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 329.6 (MH+).

Example 79


5-tert-butyl-3-(5-cyclopropyl-4-pyrrolidin-1-ylpyridin-2-yl)-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and pyrrolidine (CAS 123-75-1) (Eq: 2) as starting materials in NMP with K₂CO₃ (Eq: 3.0), heated 1h30 at 200°C with microwave, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 313.3 (MH+).


Example 80

15 5-tert-butyl-3-(5-cyclopropyl-4-cyclopropylsulfonylpyridin-2-yl)-1,2,4-oxadiazole




To a solution of 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole (50 mg, 0.18 mmol), previously described as Example 48d, in DMA (2 mL) in a microwave vial, was added sodium cyclopropanesulfinate (CAS 910209-21-1) (46.1 mg, 0.36 mmol, Eq: 2.0) and DMAP (44 mg, 0.36 mmol, Eq: 2.0). Tube was sealed and reaction heated 2 days at 140°C. DMA was evaporated. Crude was then extracted with ethyl acetate / NaHCO₃ aqueous saturated solution. Organic layer was dried on Na₂SO₄ and evaporated. Column on SiO₂ with a gradient ethyl acetate/heptane gave 37 mg of the title compound as colorless viscous oil (Yield 59%). MS (ESI, *m/z*): 348.6 (MH+).

- 90 -


5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxyazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-methoxyazetidine (CAS 110925-17-2) (Eq: 2.0) as starting materials in ethylene glycol with Cs_2CO_3 (Eq: 3.0), heated 6 h at 100°C, and purified by preparative HPLC after filtration. MS (ESI, m/z): 329.6 (MH+).

Example 82**6-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-6-azaspiro[3.3]heptane**

10

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 2-oxa-6-azaspiro[3.3]heptane (CAS 174-78-7) (Eq: 2) as starting materials in ethylene glycol with Cs_2CO_3 (Eq: 3), heated 6 h at 100°C, and purified by preparative HPLC after filtration. MS (ESI, m/z): 341.6 (MH+).

Example 83**5-tert-butyl-3-[5-cyclopropyl-4-(2-ethoxyethoxy)pyridin-2-yl]-1,2,4-oxadiazole**

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 2-ethoxyethanol (CAS 110-80-5)


- 91 -

as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 332.6 (MH⁺).

Example 84

5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxybutan-2-yloxy)pyridin-2-yl]-1,2,4-

5 oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-methoxybutan-2-ol (CAS 53778-73-7) as starting materials, and purified by preparative HPLC without any work-up.

10 MS (ESI, *m/z*): 346.6 (MH⁺).

Example 85

5-tert-butyl-3-[5-cyclopropyl-4-[2-[(2-methylpropan-2-yl)oxy]ethoxy]pyridin-2-yl]-1,2,4-oxadiazole



15


The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and ethylene glycol mono-tert-butyl ether (CAS 7580-85-0) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 360.7 (MH⁺).

20

Example 86

5-tert-butyl-3-[5-cyclopropyl-4-[1-[(2-methylpropan-2-yl)oxy]propan-2-yloxy]pyridin-2-yl]-1,2,4-oxadiazole

- 92 -




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-tert-butoxy-propan-2-ol (CAS 57018-52-7) as starting materials, and purified by preparative HPLC without any work-up.

5 MS (ESI, *m/z*): 374.8 (MH⁺).

Example 87


5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxypropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole



10 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-methoxy-propan-2-ol (CAS 107-98-2) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 332.7 (MH⁺).


Example 88

15 **5-tert-butyl-3-[5-cyclopropyl-4-(oxan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole**




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and tetrahydro-pyran-3-ol (CAS 19752-84-2) as starting materials, and purified by preparative HPLC without any work-up.

20 MS (ESI, *m/z*): 344.6 (MH⁺).

Example 89**5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)pyridin-2-yl]-1,2,4-oxadiazole**


The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-methoxy-butanol (CAS 2517-43-3) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 346.6 (MH⁺).

Example 90**5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole**

10

The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-oxetanemethanol (CAS 6246-06-6) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 330.6 (MH⁺).

15

Example 91**5-cyclopropyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole**


The title compound was synthesized in analogy to Example 33b, using (S,Z)-5-cyclopropyl-N'-hydroxy-4-(1,1,1-trifluoropropan-2-yloxy)picolinimidamide (prepared in analogy to Example 33a but with (S)-1,1,1-trifluoropropan-2-ol for the first Example 7a)

and isobutyryl chloride (CAS 79-30-1) as starting materials, and purified by flash chromatography. MS (ESI, *m/z*): 340.1 (MH⁺).

Example 92

5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-

5 oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-ethyl-3-pyrrolidinol (CAS 30727-14-1) as starting materials, and purified by preparative HPLC without any work-up.

10 MS (ESI, *m/z*): 357.6 (MH⁺).

Example 93

5-tert-butyl-3-[5-cyclopropyl-4-(1-propan-2-ylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-

oxadiazole




15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-isopropyl-pyrrolidinol (CAS 42729-56-6) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 371.7 (MH⁺).

Example 94

20 **5-tert-butyl-3-[5-cyclopropyl-4-(2-pyrrolidin-1-ylethoxy)pyridin-2-yl]-1,2,4-**

oxadiazole


- 95 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-(2-hydroxyethyl)pyrrolidine (CAS 2955-88-6) as starting materials, and purified by preparative HPLC without any
5 work-up. MS (ESI, m/z): 357.6 (MH $^+$).

Example 95


5-tert-butyl-3-[5-cyclopropyl-4-(2-piperidin-1-ylethoxy)pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-(2-hydroxyethyl)piperidine (CAS 3040-44-6) as starting materials, and purified by preparative HPLC without any
10 work-up. MS (ESI, m/z): 371.7 (MH $^+$).

Example 96

5-tert-butyl-3-[5-cyclopropyl-4-(1-piperidin-1-ylpropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and alpha-methyl-1-piperidineethanol (CAS 934-90-7) as starting materials, and purified by preparative HPLC without any work-
20 up. MS (ESI, m/z): 385.7 (MH $^+$).

Example 97**5-tert-butyl-3-[5-cyclopropyl-4-[(1-methylpiperidin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole**

5 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-methyl-2-piperidinemethanol (CAS 20845-34-5) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 371.7 (MH⁺).


Example 98**10 2-tert-butyl-5-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,3,4-oxadiazole**

a) 5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinonitrile




To a solution of 4-chloro-5-cyclopropylpicolinonitrile (300 mg, 1.68 mmol, Eq: 1.00), previously described as Example 48b, in dry DMF (11 mL) with tetrahydro-2H-pyran-4-ol 15 (CAS 2081-44-9) (189 mg, 176 μ L, 1.85 mmol, Eq: 1.1) was added NaH (60% in oil, 73.9 mg, 1.85 mmol, Eq: 1.1). The reaction was stirred at RT 15 min then 30 min at 110°C with microwave. The solvent was partially evaporated. Extraction with ethyl acetate / NaHCO₃ saturated aqueous solution Organic layer dried on Na₂SO₄ and evaporated. Column on SiO₂ using MPLC ISCO with a gradient heptane/ethyl acetate gave 245 mg of the title 20 compound as off-white powder (Yield 59%). MS (ESI, *m/z*): 245.6 (MH⁺).

b) 5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinic acid




5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinonitrile (240 mg, 0.982 mmol, Eq: 1.00) was dissolved in HCl 25% aqueous solution (9 mL). Reaction was heated at 110°C. After 3 h reaction was complete and cooled down to RT. HCl was neutralized using 6M NaOH aqueous solution followed by NaOH pellets. Then pH adjusted to 1-2 with HCl 2M. The precipitate formed was filtered off to give 140 mg of the title compound as light yellow powder (Yield 54%). MS (ESI, *m/z*): 264.6 (MH⁺).

c) 5-cyclopropyl-N'-pivaloyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinohydrazide



10 5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinic acid (70 mg, 266 μmol, Eq: 1.00) in 1,2-Dichloroethane (1.33 mL) had thionyl chloride (47.4 mg, 29.1 μL, 399 μmol, Eq: 1.5) added to it. The reaction mixture was heated up to 90°C and left to reflux for 3 h. The reaction was complete and the reaction mixture was concentrated in vacuo. The product was used immediately in the next step and dissolved in THF (391 μL) to be reacted with 15 pivalohydrazide (35.0 mg, 292 μmol, Eq: 1.1) and triethylamine (40.4 mg, 55.6 μL, 399 μmol, Eq: 1.5) at RT overnight. The reaction mixture was then diluted with ethyl acetate, poured into NaHCO₃ aqueous solution (1M). It was then extracted with ethyl acetate and the organic layers were combined, dried, and concentrated in vacuo to be used as a crude. MS (ESI, *m/z*): 362.6 (MH⁺).

20 d) 2-tert-butyl-5-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,3,4-oxadiazole




Trifluoromethanesulfonic anhydride (97.7 mg, 58.5 μL, 346 μmol, Eq: 1.5) was added slowly to a solution of triphenylphosphine oxide (193 mg, 692 μmol, Eq: 3.0) in dry DCM

(0.231 mL) at 0°C. The reaction mixture was stirred for 5 minutes at this temperature before it was adjusted to room temperature and 5-cyclopropyl-N'-pivaloyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinohydrazide (83.4 mg, 231 µmol, Eq: 1.00), first azeotropically dried with toluene, was added. The reaction mixture was then stirred for a further 30 minutes at RT before monitoring via LC-MS showed the reaction as complete. The reaction mixture was then diluted with DCM and poured into NaHCO₃ saturated aqueous solution and extracted with DCM. The aqueous layer was then back-extracted with DCM before the organic layers were combined, dried, and concentrated in vacuo. The crude material was purified by flash chromatography (SiO₂, 10 g, gradient ethyl acetate in heptane) to give 33.9 mg of the title compound (Yield 42%). MS (ESI, *m/z*): 344.6 (MH⁺).

Example 99


5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole




15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-hydroxy-N-methylpiperidine (CAS 3554-74-3) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 357.7 (MH⁺).

Example 100

20 5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-hydroxy-N-ethylpiperidine (CAS 13444-24-1) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 371.7 (MH⁺).

Example 101**2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxy-*N,N*-diethylpropan-1-amine**

5 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 1-diethylamino-2-propanol (CAS 4402-32-8) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 373.7 (MH⁺).

Example 102


10 **3-[[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxymethyl]morpholine**



15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-hydroxymethylmorpholine (CAS 103003-01-6) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 359.6 (MH⁺).

Example 103**4-[2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxyethyl]morpholine**


- 100 -



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and N-(2-hydroxyethyl)morpholine (CAS 622-40-2) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 373.7 (MH+).

Example 104

5-tert-butyl-3-(5-cyclopropyl-4-piperidin-3-ylloxypyridin-2-yl)-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (R,S)-Boc-3-hydroxypiperidine (CAS 85275-45-2) as starting materials. The reaction was then diluted with ethyl acetate and washed with water. Organic layer was dried on Na_2SO_4 and evaporated. Product was used as a crude and directly dissolved in HCl (4M) in dioxane and stirred at RT for 2 h. The reaction mixture was purified by preparative HPLC after evaporation of the solvent.

MS (ESI, *m/z*): 343.7 (MH+).

Example 105

5-tert-butyl-3-[5-cyclopropyl-4-[(3-fluorooxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (3-fluoro-oxetane) methanol (CAS

865451-85-0) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 348.5 (MH⁺).

Example 106


5-tert-butyl-3-[5-cyclopropyl-4-[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl]-
5 1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (2,5-dimethyloxazol-4-yl)methanol (CAS 92901-94-5) as starting materials, and purified by preparative HPLC
10 without any work-up. MS (ESI, *m/z*): 369.6 (MH⁺).

Example 107

5-tert-butyl-3-[5-cyclopropyl-4-[(5-methyl-1,2-oxazol-3-yl)methoxy]pyridin-2-yl]-
1,2,4-oxadiazole




15 The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and (5-methylisoxazol-3-yl)methanol (CAS 35166-33-7) as starting materials, and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 355.6 (MH⁺).

Example 108

20 5-tert-butyl-3-[5-cyclopropyl-4-(3-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole

- 102 -




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-(methylsulfonyl)phenol (CAS 14763-61-2) as starting materials with Cs_2CO_3 (Eq: 1.5), and purified by preparative

5 HPLC without any work-up. MS (ESI, m/z): 414.5 (MH $^+$).

Example 109

5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole

a) 3-(4,6-dichloropyridin-3-yl)oxetan-3-ol



10 To a solution of 5-bromo-2,4-dichloropyridine (15 g, 66.1 mmol, Eq: 1.00) (CAS 849937-96-8) in dry THF (300 mL) cooled down to -15°C under an argon atmosphere was added isopropyl magnesium chloride, lithium chloride complex (53.4 mL, 69.4 mmol, Eq: 1.05) and the mixture was stirred at -15°C for 1 h. Slow addition of neat oxetan-3-one (5.24 g, 72.7 mmol, Eq: 1.1) to the reaction mixture cooled at -15°C and reaction mixture was let

15 to warm up to RT overnight. Reaction was monitored by LC-MS. Reaction was quenched by addition of water and was transferred into a separatory funnel. Dilution with ethyl acetate, extraction with saturated aqueous NH_4Cl and organic phase was collected. Aqueous phase was back-extracted with ethyl acetate; organic phases were combined, dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 330 g


20 SiO_2 column, eluent mixture of heptane and ethyl acetate gave 10.5 g of the desired product as a white solid (yield 72%). MS (ESI, m/z): 220.4 (MH $^+$).

b) 4-chloro-5-(3-hydroxyoxetan-3-yl)picolinonitrile




To a solution of 3-(4,6-dichloropyridin-3-yl)oxetan-3-ol (5.0 g, 22.7 mmol, Eq: 1.00) in dry DMF (100 mL) under argon atmosphere was added dicyanozinc (1.47 g, 12.5 mmol, Eq: 0.55), dppf (1.26 g, 2.27 mmol, Eq: 0.1) and Pd₂(dba)₃ (1.04 g, 1.14 mmol, Eq: 0.05). The reaction mixture was stirred at 100°C for 2 h and monitored by LC-MS. Evaporation 5 of DMF, residue was diluted with ethyl acetate and poured into a separatory funnel. Extraction with saturated aqueous NH₄Cl. Pd colloids were formed and removed by filtration through Celite. Organic phase was collected; aqueous phase was back-extracted with ethyl acetate. Organic phases were combined, dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 120 g SiO₂ column, eluent mixture of 10 heptane and ethyl acetate gave 4.1 g of the desired product (Yield 86%). MS (ESI, *m/z*): 209.0 (MH⁻).

c) 4-chloro-5-(3-fluorooxetan-3-yl)pyridine-2-carbonitrile



To a solution of 4-chloro-5-(3-hydroxyoxetan-3-yl)picolinonitrile (0.2 g, 950 μmol, Eq: 15 1.00) in dry DCM (6 mL) cooled down to -78°C was added DAST (161 mg, 132 μL, 997 μmol, Eq: 1.05). The reaction was stirred at -78°C for 15 min, let to warm up to 0°C and stirred at 0°C for 1h. Reaction was then quenched by addition of aqueous Na₂CO₃ 2M, the mixture was stirred at RT for 15 min and poured into a separatory funnel. Extraction, 20 organic phase was collected, dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 20 g SiO₂ column, eluent mixture of heptane and ethyl acetate gave 184 mg of the desired product (Yield 91%). MS (ESI, *m/z*): 213.0 (MH⁺).


d) 4-chloro-5-(3-fluorooxetan-3-yl)-N'-hydroxypyridine-2-carboximidamide



To a solution of 4-chloro-5-(3-fluorooxetan-3-yl)picolinonitrile (500 mg, 2.35 mmol, Eq: 25 1.00) in Ethanol (15 mL) was added hydroxylamine hydrochloride (196 mg, 2.82 mmol, Eq: 1.2) and triethylamine (476 mg, 656 μL, 4.7 mmol, Eq: 2.0). The reaction mixture was heated to 50°C and stirred for 3 hours. Evaporation of volatiles, residue redissolved in ethyl acetate, poured into a separatory funnel and extracted with aqueous NaHCO₃ 1M, The organic layers were dried over Na₂SO₄ and evaporated down to dryness. Flash


chromatography with a 20 g SiO₂ column, eluent mixture of heptane and ethyl acetate gave 490 mg of desired compound (Yield 84%). MS (ESI, *m/z*): 246.4 (MH⁺).

e) 5-tert-butyl-3-[4-chloro-5-(3-fluorooxetan-3-yl)pyridin-2-yl]-1,2,4-oxadiazole



5 To a solution of 4-chloro-5-(3-fluorooxetan-3-yl)-N'-hydroxypicolinimidamide (490 mg, 1.99 mmol, Eq: 1.00) in dry DMF (7 mL) under argon atmosphere was added K₂CO₃ (358 mg, 2.59 mmol, Eq: 1.3) and slowly pivaloyl chloride (CAS 3282-30-2) (265 mg, 270 μ L, 2.19 mmol, Eq: 1.1). The reaction mixture was stirred for 1 h at RT and controlled by LC-MS. The reaction was then stirred at 130°C for 1h30 and monitored by LC-MS. The 10 reaction mixture was poured into a separatory funnel, diluted with EtOAc and extracted with aqueous NaHCO₃ 1M. The organic layer was dried over Na₂SO₄ and evaporated down to dryness. Purification by flash chromatography gave 374 mg of the title compound (Yield 54%). MS (ESI, *m/z*): 312.5 (MH⁺).

f) 5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole




15

To a solution of 5-tert-butyl-3-(4-chloro-5-(3-fluorooxetan-3-yl)pyridin-2-yl)-1,2,4-oxadiazole (50 mg, 144 μ mol, Eq: 1.00) in dry DMF (1 mL) were added NaH (6.35 mg, 159 μ mol, Eq: 1.1) and tetrahydropyran-4-ol (16.2 mg, 159 μ mol, Eq: 1.1) (CAS 2081-44-9). The reaction was stirred at RT for 15 min and then stirred at 110°C for 30 min under 20 microwave radiation, reaction was monitored by LC-MS. Reaction was quenched by addition of few drops of water, and mixture was directly purified by preparative HPLC with any work-up procedure giving 43 mg of the title compound. MS (ESI, *m/z*): 378.6 (MH⁺).

Example 110

25 **5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole**

- 105 -




The title compound was synthesized in analogy to Example 109f, using 5-tert-butyl-3-(4-chloro-5-(3-fluorooxetan-3-yl)pyridin-2-yl)-1,2,4-oxadiazole and 4-fluorophenol (CAS 371-41-5) as starting materials, and purified by preparative HPLC without any work-up.

5 MS (ESI, *m/z*): 388.5 (MH⁺).

Example 111

3-[2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-5*H*-1,3-oxazol-4-yl]-5-methyl-1,2,4-oxadiazole

a) N-(1-(benzyloxy)propan-2-ylidene)-2-methylpropane-2-sulfinamide




10

To a solution of 1-(benzyloxy)propan-2-one (4.0 g, 21.9 mmol, Eq: 1.00) (CAS 22539-93-1) in dry THF (100 mL) under argon atmosphere was added 2-methylpropane-2-sulfinamide (2.79 g, 23.0 mmol, Eq: 1.05) (CAS 146374-27-8) and Titanium(IV) ethoxide (5.25 g, 4.83 mL, 23.0 mmol, Eq: 1.05). The reaction mixture was stirred at 70°C

15 overnight. Reaction was cooled down to RT and stirred during quenching by addition of 10 mL of aqueous saturated NaCl solution. The heterogenous mixture was stirred for 20 min, then filtered through a pad of Celite and finally the filtrate was concentrated, diluted with ethyl acetate and extracted with aqueous saturated NaCl solution. Organic phase collected, dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 120 g 20 SiO₂ column, eluent mixture of heptane and ethyl acetate, gave 2.62 g of the title compound as yellow oil (Yield 45%). MS (ESI, *m/z*): 268.6 (MH⁺).


b) N-(1-(benzyloxy)-2-cyanopropan-2-yl)-2-methylpropane-2-sulfinamide



To a solution of N-(1-(benzyloxy)propan-2-ylidene)-2-methylpropane-2-sulfinamide (2.6 g, 9.72 mmol, Eq: 1.00) in dry THF (45 mL) under argon atmosphere was added CsF (1.62 g, 10.7 mmol, Eq: 1.1) followed by trimethylsilyl cyanide (1.06 g, 1.43 mL, 10.7 mmol, Eq: 1.1). The reaction mixture was stirred at RT overnight and monitored by TLC (ethyl acetate, spray reagent KMnO_4). Concentration in vacuo, dilution with ethyl acetate, extraction with water, organic phase was brined before drying over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 70 g SiO_2 column, eluent mixture of heptane and ethyl acetate, gave 2.55 g of the desired product (Yield 89%). MS (ESI, m/z): 295.5 (MH^+).

5

10 c) 3-(benzyloxy)-2-(1,1-dimethylethylsulfinamido)-N'-hydroxy-2-methylpropanimidamide




To a suspension of potassium carbonate (2.44 g, 17.6 mmol, Eq: 1.5) in dry ethanol (40 mL) under argon atmosphere was added hydroxylamine hydrochloride (858 mg, 12.3 mmol, Eq: 1.05) and the mixture was stirred at RT for 20 min. Addition of a solution of N-(1-(benzyloxy)-2-cyanopropan-2-yl)-2-methylpropane-2-sulfinamide (3.46 g, 11.8 mmol, Eq: 1.00) in dry ethanol (30 mL) to the former reaction mixture. The reaction mixture was stirred at 55°C overnight and monitored by TLC (ethyl acetate, UV 254nm and spray reagent KMnO_4). Evaporation of volatiles, residue suspended in ethyl acetate, extraction with aqueous Na_2CO_3 2M, aqueous phase back-extracted with ethyl acetate, organic phase were combined, dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 50 g SiO_2 column, eluent mixture of DCM and methanol, gave 3.1 g of the title compound as a white solid (Yield 81%). MS (ESI, m/z): 328.6 (MH^+).

15

20

d) N-(1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-2-methylpropane-2-sulfinamide




25

To a solution of 3-(benzyloxy)-2-(1,1-dimethylethylsulfinamido)-N'-hydroxy-2-methylpropanimidamide (3.1 g, 9.47 mmol, Eq: 1.00) in dry DMF (50 mL) under argon atmosphere was added potassium carbonate (1.57 g, 11.4 mmol, Eq: 1.2) and acetic

anhydride (967 mg, 893 μ L, 9.47 mmol, Eq: 1.0). The reaction mixture was stirred at RT for 1 h and was monitored by LC-MS to control the formation of the acetylated intermediate. The reaction was then stirred at 120°C for 2 h, monitoring was done by LC-MS. Evaporation of volatiles, residue redissolved in ethyl acetate, extraction with aqueous 5 NaHCO_3 1M, aqueous phase back-extracted with ethyl acetate, organic phases were combined, dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 120 g SiO_2 column, eluent mixture of heptane and ethyl acetate, gave 2.25 g of title compound as yellow oil (Yield 68%). MS (ESI, m/z): 352.6 (MH $^+$).


e) 1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-amine



10

To a solution of N-(1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-2-methylpropane-2-sulfonamide (2.25 g, 6.4 mmol, Eq: 1.00) in MeOH (25 mL) was added HCl 4M in Dioxane (4.8 mL, 19.2 mmol, Eq: 3.0). The reaction mixture was stirred at RT for 1 h and monitored by LC-MS. Evaporation of volatiles, residue redissolved in ethyl 15 acetate, extraction with aqueous Na_2CO_3 2M. Aqueous phase was back-extracted with ethyl acetate and organic phases were combined, dried over Na_2SO_4 and evaporated down to dryness. Flash chromatography with a 50 g SiO_2 column, eluent mixture of heptane and ethyl acetate, gave 1.52 g of desired product as light yellow oil (Yield 96%). MS (ESI, m/z): 248.6 (MH $^+$).

20 f) N-(1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinamide




To a solution of 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (0.4 g, 1.53 mmol, Eq: 1.00), previously described as Example 7e, in dry DMF (10 mL) under argon 25 atmosphere was added TBTU (516 mg, 1.61 mmol, Eq: 1.05) and triethylamine (186 mg,

- 108 -


256 μ L, 1.84 mmol, Eq: 1.2). The reaction mixture was stirred at RT for 30 min and 1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-amine (398 mg, 1.61 mmol, Eq: 1.05) was then added to the reaction. The reaction was then stirred at RT overnight and monitored by LC-MS. Evaporation of DMF. Residue was redissolved in ethyl acetate and 5 extracted with aqueous NaHCO₃ 1M. Organic phase dried over Na₂SO₄ and evaporated down to dryness. Flash chromatography with a 50 g SiO₂ column, eluent mixture of heptane and ethyl acetate gave 805 mg of the desired product (Yield 93%). MS (ESI, *m/z*): 491.5 (MH⁺).

10 g) 5-cyclopropyl-N-(1-hydroxy-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-4-(2,2,2-trifluoroethoxy)picolinamide




To a solution of N-(1-(benzyloxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinamide (0.1 g, 204 μ mol, Eq: 1.00) in dry DCM (1 mL) cooled down to 0°C under argon atmosphere was added BBr₃ solution 1.0M in 15 DCM (224 μ L, 224 μ mol, Eq: 1.1). The reaction mixture was stirred at 0°C for 15 min and then stirred at RT for 1 h, reaction was monitored by LC-MS. Reaction was diluted with DCM, quenched by addition of aqueous Na₂CO₃ 2M and mixture was stirred for 10 min. Mixture was poured into a separatory funnel, organic phase was collected, aqueous phase was back-extracted with DCM, organic phases were combined, dried over Na₂SO₄ and 20 evaporated down to dryness. Flash chromatography with a 10 g SiO₂ column, eluent mixture of heptane and ethyl acetate, gave 80 mg of the desired product (Yield 92%). MS (ESI, *m/z*): 401.5 (MH⁺).

h) 2-(5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinamido)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propyl 4-methylbenzenesulfonate



To a solution of 5-cyclopropyl-N-(1-hydroxy-2-(5-methyl-1,2,4-oxadiazol-3-yl)propan-2-yl)-4-(2,2,2-trifluoroethoxy)picolinamide (0.1 g, 250 μ mol, Eq: 1.00) in dry DCM (2 ml) was added DMAP (15.3 mg, 125 μ mol, Eq: 0.5), K_2CO_3 (48.3 mg, 350 μ mol, Eq: 1.4) followed by addition of 4-methylbenzene-1-sulfonyl chloride (47.6 mg, 250 μ mol, Eq: 5.0). The reaction mixture was stirred at RT overnight and monitored by LC-MS. Reaction diluted with DCM and water, poured into a separatory funnel, extracted and organic phase was collected. Organic phase was dried over Na_2SO_4 and evaporated down to dryness. Crude was used for the next step without any purification. MS (ESI, m/z): 555.4 (MH $+$).

10 i) 3-(2-(5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)-4-methyl-4,5-dihydrooxazol-4-yl)-5-methyl-1,2,4-oxadiazole




To a solution of 2-(5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinamido)-2-(5-methyl-1,2,4-oxadiazol-3-yl)propyl 4-methylbenzenesulfonate (0.06 g, 108 μ mol, Eq: 1.00) in dry DMF (1 mL) was added triethylamine (16.4 mg, 22.6 μ l, 162 μ mol, Eq: 1.5) and 3,3-difluoroazetidine hydrochloride (CAS 288315-03-7) (16.8 mg, 130 μ mol, Eq: 1.2). The reaction mixture was stirred at 80°C for 45 min under microwave radiation and reaction was monitored by LC-MS which showed conversion to a side product from an intramolecular ring closure to an oxazolidine. Reaction was directly purified by preparative HPLC without any purification and gave 6.2 mg of the title compound. MS (ESI, m/z): 20 383.5 (MH $+$).

Example 112


5-tert-butyl-3-(6-chloro-5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridin-2-yl)-1,2,4-oxadiazole

25 a) 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridine 1-oxide



To a solution of 5-tert-butyl-3-(5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridin-2-yl)-1,2,4-oxadiazole (326 mg, 887 μ mol, Eq: 1.00), previously described as Example 53, in dry DCM (4.93 mL) was added *m*-CPBA (459 mg, 1.33 mmol, Eq: 1.5) and the reaction stirred 5 overnight at RT. Extraction with NaHCO₃/DCM. Organic layer was dried on Na₂SO₄ and evaporated. Purification by flash chromatography on SiO₂ column with a gradient DCM and methanol gave 445 mg of the title compound (Yield 78%). MS (ESI, *m/z*): 384.6 (MH⁺).

10 b) 5-tert-butyl-3-(6-chloro-5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridin-2-yl)-1,2,4-oxadiazole




2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridine 1-oxide (123 mg, 321 μ mol, Eq: 1.00) was dissolved in a mixture of DCM/DMF : 1/1 (2.8 mL). The mixture was cooled down to 0°C and oxalyl chloride (204 mg, 139 μ L, 1.6 mmol, Eq: 15 5.0) was slowly added. Reaction was stirred at 0°C for 30 min and then the temperature was allowed to reach RT and reacted overnight. The reaction was cooled down to 0°C and quenched by addition of aqueous Na₂CO₃ and stirred for 15 min at 0°C. The mixture was diluted with ethyl acetate and extracted with aqueous Na₂CO₃. Organic phase was collected; aqueous phase was back-extracted with ethyl acetate. Organic phases were 20 combined, dried over Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography on SiO₂ using MPLC ISCO with a gradient heptane/ethyl acetate giving 15 mg of the title compound as colorless viscous oil. MS (ESI, *m/z*): 402.5 (MH⁺).

Example 113

2-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,3,4-oxadiazole


a) 5-cyclopropyl-N'-pivaloyl-4-(2,2,2-trifluoroethoxy)picolinohydrazide



5 5-cyclopropyl-4-(2,2,2-trifluoroethoxy)picolinic acid (100 mg, 383 mmol, Eq: 1.00), previously described as Example 7e, in DCM (1.91 mL) had oxalyl chloride (50 μ L, 0.574 mmol, Eq: 1.5) and DMF (2 μ L, 0.019 mmol, Eq: 0.05) added to it. The reaction was deemed to be complete and the reaction mixture was concentrated in vacuo. The product was used immediately in the next step and dissolved in THF (563 μ L) to be reacted with

10 pivalohydrazide (55.0 mg, 459 μ mol, Eq: 1.2) (CAS 42826-42-6) and triethylamine (58.1 mg, 80.0 μ L, 574 μ mol, Eq: 1.5) at RT overnight. The reaction mixture was then diluted with ethyl acetate, poured into NaHCO₃ 1M solution. It was then extracted with ethyl acetate and the organic layers were combined, dried, and concentrated in vacuo to give 130 mg of the title compound used as crude (Yield 94%). MS (ESI, *m/z*): 360.6 (MH⁺).

15 b) 2-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,3,4-oxadiazole



Trifluoromethanesulfonic anhydride (153 mg, 91.7 μ L, 543 μ mol, Eq: 1.5) was added slowly to a solution of triphenylphosphine oxide (302 mg, 1.09 mmol, Eq: 3.0) in dry DCM (0.231 mL) at 0°C. The reaction mixture was stirred for 5 minutes at this

20 temperature before it was adjusted to room temperature and 5-cyclopropyl-N'-pivaloyl-4-(2,2,2-trifluoroethoxy)picolinohydrazide (130 mg, 362 μ mol, eq: 1.00) previously azeotropically dried with toluene, was added. The reaction mixture was then stirred for a further 30 minutes at RT before monitoring via LC-MS showed the reaction as complete. The reaction mixture was then diluted with DCM and poured into NaHCO₃ saturated

25 aqueous solution and extracted with DCM. The aqueous layer was then back-extracted


with DCM before the organic layers were combined, dried, and concentrated in vacuo. The crude material was purified by flash chromatography (SiO₂, 10 g, gradient ethyl acetate in heptane) to give 56 mg of the title product as white solid (45 % yield). MS (ESI, *m/z*): 342.6 (MH⁺).

5

Example 114

5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole


a) 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridine 1-oxide



10 To a solution of 5-tert-butyl-3-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole (64 mg, 186 µmol, Eq: 1.00), previously described as Example 63, in dry DCM (1.04 mL) was added *m*-CPBA (96.5 mg, 280 µmol, Eq: 1.5). The reaction was stirred for 1 h at RT. Extraction NaHCO₃/DCM. Organic layer was dried on Na₂SO₄ and evaporated. Purification by flash chromatography (SiO₂, 70 g, eluent: ethyl acetate/heptane) gave 59 mg of the desired compound (Yield 88%). MS (ESI, *m/z*): 360.6 (MH⁺).

15

b) 5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole




20 2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridine 1-oxide (56 mg, 0.156 mmol, Eq: 1.00) was dissolved in a mixture of DCM/DMF : 1/1 (1.3 mL). The mixture was cooled down to 0°C and oxalyl chloride (98.9 mg, 67.3 µL, 779 µmol, Eq: 5.0) was slowly added. Reaction was stirred at 0°C for 20 min and then the temperature was allowed to reach RT and reacted overnight. Another 1.5 eq of oxalyl chloride was added and stirred for 1.5 h. The reaction was then cooled down to 0°C

and quenched by addition of aqueous Na_2CO_3 and stirred for 15 min at 0°C. The mixture was diluted with ethyl acetate and extracted with aqueous Na_2CO_3 . Organic phase was collected; aqueous phase was back-extracted with ethyl acetate. Organic phases were combined, dried over Na_2SO_4 and evaporated down to dryness. The crude material was 5 purified by flash chromatography (SiO_2 , 5 g, ethyl acetate/heptane) giving 21 mg of the title compound as colorless oil (Yield 35%). MS (ESI, m/z): 378.5 (MH $^+$).

Example 115

5-tert-butyl-3-[5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole


a) 5-cyclopropyl-4-(2,2-difluoroethoxy)picolinonitrile



10

Sodium hydride (123 mg, 3.08 mmol, Eq: 1.1) was added to a solution of 4-chloro-5-cyclopropylpicolinonitrile (500 mg, 2.8 mmol, Eq: 1.00), previously described as Example 48b, and 2,2-difluoroethanol (253 mg, 3.08 mmol, Eq: 1.1) (CAS 359-13-7) in DMF (10 mL) at RT. and stirred for 3 hours. The 5-fold volume of water was added, followed by 15 extraction with EtOAc, washing with brine. Organic layer was dried on MgSO_4 , concentrated in vacuo and chromatographed on SiO_2 with DCM to afford 508 mg of the title compound as a dark-yellow solid (Yield 80%). MS (ESI, m/z): 225.2 (MH $^+$).

b) 5-tert-butyl-3-[5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole




20 To a solution of 5-cyclopropyl-4-(2,2-difluoroethoxy)picolinonitrile (120 mg, 0.535 mmol, Eq: 1.00) in EtOH (3.5 mL) was added triethylamine (149 μL , 1.07 mmol, Eq: 2.0) and hydroxylamine hydrochloride (55.8 mg, 0.803 mmol, Eq: 1.5) and the mixture heated 30 min at 90°C with microwave. 1 M NaHCO_3 was added and it was extracted with DCM. Drying on MgSO_4 and concentration in vacuo afforded 60 mg of the compound as light-yellow solid, this was used without further purification and dissolved in DMF (2.00 mL). 25 Then triethylamine (29.0 mg, 40.0 μL , 287 μmol , Eq: 1.2) and pivaloyl chloride (31.4 mg,

32 μ L, 260 μ mol, Eq: 1.1) were added at RT and after 30 minutes stirring, the solution was heated at 130 $^{\circ}$ C with microwave for 30 minutes. The mixture was diluted with water and extracted with ethyl acetate, washed with brine, dried on MgSO₄ and concentration in vacuo followed by column chromatography (SiO₂, ethyl acetate in heptane) afforded 45 mg of the title compound (Yield 59%). MS (ESI, *m/z*): 324.5 (MH⁺).

Example 116


5-tert-butyl-3-[5-cyclopropyl-4-(2-fluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 115, using 4-chloro-5-cyclopropylpicolinonitrile, previously described as Example 48b, and 2-fluoroethanol (CAS 371-62-0) as starting materials. MS (ESI, *m/z*): 306.5 (MH⁺).

Example 117


5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 2-(hydroxymethyl)pyridine (CAS 586-98-1) as starting materials, heated 30 min at 120 $^{\circ}$ C with microwave and purified by preparative HPLC without any work-up. MS (ESI, *m/z*): 351.6 (MH⁺).

Example 118

20 5-tert-butyl-3-[5-cyclopropyl-4-[(5-fluoropyridin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole




The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 5-fluoro-2-hydroxymethylpyridine (CAS 802325-29-7) as starting materials, heated 30 min at 110°C under microwave radiation. The mixture was diluted with ethyl acetate and extracted with aqueous Na₂CO₃. Organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The organic phases were combined, dried over Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography (SiO₂, 5 g, ethyl acetate/heptane). MS (ESI, m/z): 369.6 (MH⁺).


10

Example 119


5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 48e, using 5-tert-butyl-3-(4-chloro-5-cyclopropylpyridin-2-yl)-1,2,4-oxadiazole and 3-(hydroxymethyl)pyridine (CAS 100-55-0) as starting materials, heated 30 min at 110°C under microwave radiation. The mixture was diluted with ethyl acetate and extracted with aqueous Na₂CO₃. The organic phase was collected and the aqueous phase was back-extracted with ethyl acetate. The organic phases were combined, dried over Na₂SO₄ and evaporated down to dryness. The crude material was purified by flash chromatography (SiO₂, 5 g, ethyl acetate/heptane). MS (ESI, m/z): 351.6 (MH⁺).

Example 120**2-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,3,4-oxadiazole**


5 The title compound was synthesized in a similar manner to Example 98, using the corresponding nitrile 5-cyclopropyl-4-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridine-2-carbonitrile generated from (S)-1,1,1-Trifluoropropan-2-ol (CAS 3539-97-7) according to example 7a-d. MS (ESI, *m/z*): 356.6 (MH⁺).

Example 121**10 3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole**

15 The title compound was synthesized in analogy to Example 51c, using 5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)picolinic acid from example 98b. MS (ESI, *m/z*): 344.5 (MH⁺).


Example 122**3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole**

20 a) tert-butyl (2S)-2-[[2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-5-cyclopropylpyridin-4-yl]oxymethyl]pyrrolidine-1-carboxylate




The title compound was synthesized in analogy to Example 51d using Boc-L-prolinol (CAS 69610-40-8). MS (ESI, *m/z*): 443.7 (MH⁺).

b) 3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-pyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole



tert-butyl (2S)-2-[[2-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-5-cyclopropylpyridin-4-yl]oxymethyl]pyrrolidine-1-carboxylate (364 mg, 823 μ mol, Eq: 1.00) was dissolved in a 4M solution of hydrochloric acid in 1,4-dioxane (19.5 ml, 78.1 mmol, Eq: 95) and then 10 stirred at rt for 1.5 hours and monitored by LC-MS. The solvent was evaporated and the reaction mixture was diluted with ethyl acetate and washed with NaHCO₃ and the organic phase was collected, dried over Na₂SO₄ and evaporated. The crude material was purified by flash chromatography (SiO₂, 20g, ethyl acetate/heptane) to afford 104 mg of the title compound as a light yellow powder (Yield 37%). MS (ESI, *m/z*): 343.6 (MH⁺).

15 c) 3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole



To a solution of 3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-pyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole (95 mg, 277 μ mol, Eq: 1.00) and formaldehyde (295 mg, 360 μ l, 3.63

mmol, Eq: 13.1) in dichloromethane (1.8 mL) was added sodium triacetoxyborohydride (300 mg, 1.42 mmol, Eq: 5.1). The reaction was stirred 3 hours at rt, and monitored by LC-MS. The mixture was diluted with dichloromethane and washed with 1 N NaOH. The organic phase was dried over Na_2SO_4 and evaporated. The crude material was purified by 5 flash chromatography (SiO_2 , 10g, ethyl acetate/heptane) to afford 54 mg of the title compound as light yellow oil (Yield 54%). MS (ESI, *m/z*): 357.6 (MH $^+$).


Example 123

3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole

a) 5-cyclopropyl-4-(2,2-difluoroethoxy)picolinic acid

10 5-cyclopropyl-4-(2,2-difluoroethoxy)picolinonitrile (350 mg, 1.56 mmol, Eq: 1.00, previously described as Example 115a, was dissolved in aqueous HCl 25% (16.8 g, 15 ml, 115 mmol, Eq: 73.8). Reaction was heated at 110°C for 1 hour and then cooled down to rt. HCl was neutralized using 6M NaOH aq. sol. Then pH adjusted to 1-2 with HCl 2M. The precipitate formed was then filtered. The remaining salt was precipitated with ethanol and 15 filtered giving the title compound as a light yellow solid. MS (ESI, *m/z*): 244.3 (MH $^+$).

b) 3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole



The title compound was synthesized in analogy to Example 51c, using 5-cyclopropyl-4-(2,2-difluoroethoxy)picolinic acid. MS (ESI, *m/z*): 324.6 (MH $^+$).

Example 124

Pharmacological tests

The following tests were carried out in order to determine the activity of the compounds of formula I:

Radioligand binding assay

25 The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using recommended amounts of membrane preparations (PerkinElmer) of

human embryonic kidney (HEK) cells expressing the human CNR1 or CNR2 receptors in conjunction with 1.5 or 2.6 nM [³H]-CP-55,940 (Perkin Elmer) as radioligand, respectively. Binding was performed in binding buffer (50 mM Tris, 5 mM MgCl₂, 2.5 mM EDTA, and 0.5% (wt/vol) fatty acid free BSA, pH 7.4 for CB1 receptor and 50 mM 5 Tris, 5 mM MgCl₂, 2.5 mM EGTA, and 0.1% (wt/vol) fatty acid free BSA, pH 7.4 for CB2 receptor) in a total volume of 0.2 ml for 1h at 30°C shaking. The reaction was terminated by rapid filtration through microfiltration plates coated with 0.5% polyethylenimine (UniFilter GF/B filter plate; Packard). Bound radioactivity was analyzed for Ki using nonlinear regression analysis (Activity Base, ID Business Solution, Limited), with the Kd 10 values for [³H]CP55,940 determined from saturation experiments. The compounds of formula (I) show an excellent affinity for the CB2 receptor with affinities below 10 μM, more particularly of 1 nM to 3 μM and most particularly of 1 nM to 100 nM.

cAMP Assay

CHO cells expressing human CB1 or CB2 receptors are seeded 17-24 hours prior to the 15 experiment 50.000 cells per well in a black 96 well plate with flat clear bottom (Corning Costar #3904) in DMEM (Invitrogen No. 31331), 1x HT supplement, with 10 % fetal calf serum and incubated at 5% CO₂ and 37°C in a humidified incubator. The growth medium was exchanged with Krebs Ringer Bicarbonate buffer with 1 mM IBMX and incubated at 30 °C for 30 min. Compounds were added to a final assay volume of 100 μl and incubated 20 for 30 min at 30 °C. Using the cAMP-Nano-TRF detection kit the assay (Roche Diagnostics) was stopped by the addition of 50 μl lysis reagent (Tris, NaCl, 1.5% Triton X100, 2.5% NP40, 10% NaN₃) and 50 μl detection solutions (20 μM mAb Alexa700-cAMP 1:1, and 48 μM Ruthenium-2-AHA-cAMP) and shaken for 2h at room temperature. The time-resolved energy transfer is measured by a TRF reader (Evotec Technologies 25 GmbH), equipped with a ND:YAG laser as excitation source. The plate is measured twice with the excitation at 355 nm and at the emission with a delay of 100 ns and a gate of 100 ns, total exposure time 10s at 730 (bandwidth 30 nm) or 645 nm (bandwidth 75 nm), respectively. The FRET signal is calculated as follows: FRET = T730-Alexa730-P(T645-B645) with P = Ru730-B730/Ru645-B645, where T730 is the test well measured at 30 730 nM, T645 is the test well measured at 645 nm, B730 and B645 are the buffer controls at 730 nm and 645 nm, respectively. cAMP content is determined from the function of a standard curve spanning from 10 μM to 0.13 nM cAMP.

EC₅₀ values were determined using Activity Base analysis (ID Business Solution, Limited). The EC₅₀ values for a wide range of cannabinoid agonists generated from this assay were 35 in agreement with the values published in the scientific literature.

The compounds of the invention are CB2 agonists with EC₅₀ below 0.5 µM and selectivity versus CB1 in the corresponding assay of at least 10 fold. Particular compound of the invention are CB2 agonists with EC₅₀ below 0.05 µM and selectivity versus CB1 in the corresponding assay of at least 500 fold.

5 For example, the following compounds showed the following human EC₅₀ values in the functional cAMP assay described above (in µM):

Example	EC50 CB2 human	EC50 CB1 human	Example	EC50 CB2 human	EC50 CB1 human
1	0.0257	>10	63	0.0043	>10
2	0.0231	>10	64	0.0875	>10
3	0.0012	>10	65	0.0017	0.17031
4	0.0021	>10	66	0.009	>10
5	0.0691	>10	67	0.4343	>10
6	0.001	0.0092	68	0.0726	>10
7	0.0111	>10	69	0.009	>10
8	0.0213	>10	70	0.0057	>10
9	0.0158	>10	71	0.2795	>10
10	0.0008	>10	72	0.0454	>10
11	0.0006	>10	73	0.0572	>10
12	0.0466	>10	74	0.0047	>10
13	0.0319	>10	75	0.2877	>10
14	0.0037	>10	76	0.0193	>10
15	0.0198	>10	77	0.0021	>10
16	0.3426	>10	78	0.0422	>10
17	0.0205	>10	79	0.009	>10
18	0.1104	>10	80	0.0475	>10
19	0.0137	>10	81	0.0211	>10

20	0.0037	>10	82	0.0379	>10
21	0.07	>10	83	0.0301	>10
22	0.0042	3.67542	84	0.0501	>10
23	0.0352	>10	85	0.0356	1.33751
24	0.0043	0.58087	86	0.0482	1.40191
25	0.135	>10	87	0.1127	>10
26	0.0308	>10	88	0.0529	>10
27	0.0035	>10	89	0.0162	>10
28	0.016	>10	90	0.0118	>10
29	0.7967	>10	91	0.6412	>10
30	0.0026	>10	92	0.0751	0.76771
31	0.0194	>10	93	0.0119	0.23504
32	0.0086	>10	94	0.0602	>10
33	0.0069	>10	95	0.0261	>10
34	0.0147	>10	96	0.0759	1.01189
35	0.0328	>10	97	0.019	>10
36	0.0209	>10	98	0.042	>10
37	0.2359	>10	99	0.3174	>10
38	0.1283	>10	100	0.5179	>10
39	0.4344	>10	101	0.1423	>10
40	0.0022	>10	102	0.0718	>10
41	0.0539	>10	103	0.0289	>10
42	0.0023	>10	104	0.0698	>10
43	0.0409	>10	105	0.0291	>10
44	0.0159	>10	106	0.1279	>10

45	0.0778	>10	107	0.0958	>10
46	0.1798	>10	108	0.0698	>10
47	0.1659	>10	109	0.162	>10
48	0.019	>10	110	0.103	>10
49	0.0515	>10	111	0.0576	>10
50	0.0458	>10	112	0.0048	0.07317
51	0.0618	>10	113	0.0225	>10
52	0.0131	>10	114	0.0037	0.45539
53	0.0014	0.05506	115	0.002	>10
54	0.0331	>10	116	0.0155	>10
55	0.0077	>10	117	0.0539	>10
56	0.0447	>10	118	0.035	>10
57	0.0134	>10	119	0.047	>10
58	0.0156	>10	120	0.063	>10
59	0.0481	>10	121	0.001	>10
60	0.4476	>10	122	0.146	>10
61	0.0062	>10	123	0.002	>10
62	0.0178	>10			

Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per tablet</u>	
Kernel:		
Compound of formula (I)	10.0 mg	200.0 mg
Microcrystalline cellulose	23.5 mg	43.5 mg
Lactose hydrous	60.0 mg	70.0 mg
Povidone K30	12.5 mg	15.0 mg
Sodium starch glycolate	12.5 mg	17.0 mg
Magnesium stearate	1.5 mg	4.5 mg
(Kernel Weight)	120.0 mg	350.0 mg
Film Coat:		
Hydroxypropyl methyl cellulose	3.5 mg	7.0 mg
Polyethylene glycol 6000	0.8 mg	1.6 mg
Talc	1.3 mg	2.6 mg
Iron oxide (yellow)	0.8 mg	1.6 mg
Titan dioxide	0.8 mg	1.6 mg

The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is then mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 5 120 or 350 mg respectively. The kernels are lacquered with an aq. solution / suspension of the above mentioned film coat.

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per capsule</u>
Compound of formula (I)	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:


Compound of formula (I)	3.0 mg
Polyethylene glycol 400	150.0 mg
Acetic acid	q.s. ad pH 5.0
Water for injection solutions	ad 1.0 ml

5

The active ingredient is dissolved in a mixture of Polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by addition of acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.


Claims

1. A compound of formula (I)




wherein


5 A is A1, A2, A3, A4 A5, A6, A7 or A8




A1




A3




A4




A5



A6



A7



A8

;

R¹ is hydrogen or halogen;

R² is halogen, cycloalkyl, haloazetidinyl, 6-oxa-1-aza-spiro[3.3]heptyl or alkylsulfonyl;

10 R³ is -OR⁸, pyrrolidinyl, halopyrrolidinyl, hydroxypyrrolidinyl, morpholinyl, cycloalkylsulfonyl, alkoxyazetidinyl, 2-oxa-6-aza-spiro[3.3]heptyl or 2-oxa-7-azaspiro[3.4]heptyl;

R⁴ is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl, hydroxycycloalkyl, alkylcycloalkyl, aminocarbonylcycloalkyl, phenyl, phenylalkyl, alkyloxetanyl, azetidinyl or aminooxetanyl;

15 R⁵ is hydrogen, alkyl or alkyloxadiazolyl;

or R⁴ and R⁵, together with the carbon atom to which they are attached, form cycloalkyl;

R⁶ is alkyl;

R^7 is alkyl; and

R^8 is haloalkyl, alkoxyalkyl, cycloalkylalkyl, haloalkyl, halophenyl, oxetanyl, oxetanylalkyl, alkyloxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl, alkylsulfonylphenyl, alkylpyrrolidinyl, alkylpyrrolidinylalkyl, azetidinyl, morpholinylalkyl, tetrahydropyranyl, pyrrolidinylalkyl, piperidinyl, piperidinylalkyl, alkylpiperidinylalkyl, alkylpiperidinyl, dialkylaminoalkyl, pyridinylalkyl, halooxetanylalkyl, dialkyloxazolylalkyl, alkyloxazolylalkyl halopyridinylalkyl or morpholinyl;

or a pharmaceutically acceptable salt or ester thereof.

- 10 2. A compound according to claim 1, wherein A is A1 or A2.
3. A compound according to claim 1 or 2, wherein R^1 is hydrogen or chloro.
4. A compound according to any one of claims 1 to 3, wherein R^1 is hydrogen.
5. A compound according to any one of claims 1 to 4, wherein R^2 is cycloalkyl.
6. A compound according to any one of claims 1 to 5, wherein R^2 is cyclopropyl.
- 15 7. A compound according to any one of claims 1 to 6, wherein R^3 is $-OR^8$.
8. A compound according to any one of claims 1 to 7, wherein R^4 is alkyl.
9. A compound according to any one of claims 1 to 8, wherein R^4 is butyl.
10. A compound according to any one of claims 1 to 9, wherein R^5 is hydrogen, ethyl or methyloxadiazolyl, or R^4 and R^5 , together with the carbon atom to which they are attached, form cyclohexyl.
- 20 11. A compound according to any one of claims 1 to 10, wherein R^6 is methyl.
12. A compound according to any one of claims 1 to 11, wherein R^7 is methyl or isopropyl.
13. A compound according to any one of claims 1 to 12, wherein R^8 is haloalkyl, alkoxyalkyl, halophenyl, alkyloxetanylalkyl, oxetanylalkyl, tetrahydrofuranyl, tetrahydrofuranylalkyl, tetrahydropyranyl, halopyridinylalkyl or morpholinyl.
- 25 14. A compound according to any one of claims 1 to 13, wherein R^8 is trifluoromethyl, ethoxyethyl, methoxybutyl, fluorophenyl, oxetanylmehtyl, methyloxetanylmehtyl,

tetrahydrofuranyl, tetrahydrofuran-ylmethyl, tetrahydropyran-yl, difluoroethyl, fluoropyridinylmethyl or morpholinyl.

15. A compound according to any one of claims 1 to 14 selected from

5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole;

5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-phenyl-1,2,4-oxadiazole;

3-cyclopropyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-cyclopentyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

10 3-benzyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-cyclopropyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-(trifluoromethyl)-1,2,4-oxadiazole;

5-cyclopropyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

20 3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(methoxymethyl)-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-ethyl-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

25 3-cyclopropyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-methyl-1,2,4-oxadiazole;

3-tert-butyl-5-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5 [3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]methanol;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(trifluoromethyl)-1,2,4-oxadiazole;

10 (4S)-4-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4,5-dihydro-1,3-oxazole;

2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-4-ethyl-4,5-dihydro-1,3-oxazole;

2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;

15 1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

20 1-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropane-1-carboxamide;

2-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propan-2-ol;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

25 3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

5-(azetidin-3-yl)-3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4,4-diethyl-5H-1,3-oxazole;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-oxa-1-azaspiro[4.5]dec-1-ene;

5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-(3,3-difluoroazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

5 5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

10 1-[6-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-4-(cyclopropylmethoxy)pyridin-3-yl]-6-oxa-1-azaspiro[3.3]heptane;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

15 1-[3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

20 2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5,5-dimethyl-4H-1,3-oxazole;

5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-3-propan-2-yl-1,2,4-oxadiazole;

5-tert-butyl-3-[4-(cyclopropylmethoxy)-5-methylsulfonylpyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-propan-2-yl-1,2,4-oxadiazole;

1-[3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]cyclopropan-1-ol;

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(3-methyloxetan-3-yl)-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5 5-tert-butyl-3-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

3-[5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-(1-methylcyclopropyl)-1,2,4-oxadiazole;

10 3-tert-butyl-5-[5-cyclopropyl-4-[(2R)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(4-fluorophenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole

25 3-[3-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,2,4-oxadiazol-5-yl]oxetan-3-amine;

5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-(5-tert-butyl-1H-imidazol-2-yl)-5-(3,3-difluoroazetidin-1-yl)-4-(2,2,2-trifluoroethoxy)pyridine;

5-tert-butyl-2-[5-cyclopropyl-4-(cyclopropylmethoxy)pyridin-2-yl]-1,3-oxazole;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;

5-tert-butyl-3-[5-methylsulfonyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-ethyl-4-methyl-1H-imidazol-5-one;

10 2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-(2-methylpropyl)-1H-imidazol-5-one;

2-[5-bromo-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-4-propan-2-yl-1H-imidazol-5-one;

5-tert-butyl-3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 3-[5-chloro-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-5-cyclopropyl-1,2,4-oxadiazole;

5-cyclopropyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

1-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]pyrrolidin-3-ol;

20 5-tert-butyl-3-[5-cyclopropyl-4-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(4-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

7-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-7-azaspiro[3.4]octane;

25 5-tert-butyl-3-[5-cyclopropyl-4-(3,3-difluoropyrrolidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

4-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]morpholine;

5-tert-butyl-3-(5-cyclopropyl-4-pyrrolidin-1-ylpyridin-2-yl)-1,2,4-oxadiazole;

5-tert-butyl-3-(5-cyclopropyl-4-cyclopropylsulfonylpyridin-2-yl)-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxyazetidin-1-yl)pyridin-2-yl]-1,2,4-oxadiazole;

6-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]-2-oxa-6-
5 azaspiro[3.3]heptane;

5-tert-butyl-3-[5-cyclopropyl-4-(2-ethoxyethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxybutan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[2-[(2-methylpropan-2-yl)oxy]ethoxy]pyridin-2-yl]-
10 1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[1-[(2-methylpropan-2-yl)oxy]propan-2-yloxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methoxypropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 5-tert-butyl-3-[5-cyclopropyl-4-(oxan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-cyclopropyl-3-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-
1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-propan-2-ylpyrrolidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-(2-pyrrolidin-1-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-piperidin-1-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-piperidin-1-ylpropan-2-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(1-methylpiperidin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5 2-tert-butyl-5-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,3,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-methylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(1-ethylpiperidin-3-yl)oxypyridin-2-yl]-1,2,4-oxadiazole;

10 2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxy-N,N-diethylpropan-1-amine;

3-[[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxymethyl]morpholine;

15 4-[2-[2-(5-tert-butyl-1,2,4-oxadiazol-3-yl)-5-cyclopropylpyridin-4-yl]oxyethyl]morpholine;

5-tert-butyl-3-(5-cyclopropyl-4-piperidin-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(3-fluorooxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

20 5-tert-butyl-3-[5-cyclopropyl-4-[(2,5-dimethyl-1,3-oxazol-4-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(5-methyl-1,2-oxazol-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-(3-methylsulfonylphenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-(3-fluorooxetan-3-yl)-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-[2-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-4-methyl-5H-1,3-oxazol-4-yl]-5-methyl-1,2,4-oxadiazole;

5-tert-butyl-3-(6-chloro-5-cyclopropyl-4-(4-fluorobenzyl)oxy)pyridin-2-yl]-1,2,4-oxadiazole;

5 2-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,3,4-oxadiazole;

5-tert-butyl-3-[6-chloro-5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-fluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

10 5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-[(5-fluoropyridin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(pyridin-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

15 2-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxypyridin-2-yl]-1,3,4-oxadiazole;

3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyridin-2-yl]-1,2,4-oxadiazole; and

20 3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole.

16. A compound according to any one of claims 1 to 15 selected from

5-tert-butyl-3-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-[5-cyclopropyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

25 5-tert-butyl-3-[5-cyclopropyl-4-[(3-methyloxetan-3-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-2-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(4-fluorophenoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxolan-3-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(oxan-4-yloxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(2-ethoxyethoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5-tert-butyl-3-[5-cyclopropyl-4-(3-methoxybutoxy)pyridin-2-yl]-1,2,4-oxadiazole;

5 5-tert-butyl-3-[5-cyclopropyl-4-(oxetan-3-ylmethoxy)pyridin-2-yl]-1,2,4-oxadiazole;


5-tert-butyl-3-[5-cyclopropyl-4-[(5-fluoropyridin-2-yl)methoxy]pyridin-2-yl]-1,2,4-oxadiazole;

3-tert-butyl-5-(5-cyclopropyl-4-(tetrahydro-2H-pyran-4-yloxy)pyridin-2-yl)-1,2,4-oxadiazole; and


10 3-tert-butyl-5-(5-cyclopropyl-4-(2,2-difluoroethoxy)pyridin-2-yl)-1,2,4-oxadiazole.

17. A process for the manufacture of a compound of formula (I) according to any one of claims 1 to 16 comprising one of the following steps:

(a) the heating of a compound of formula (A)




15 (b) the heating of a compound of formula (B)




(c) the reaction of a compound of formula (C)

- 136 -



in the presence of haloazetidine or 6-oxa-1-aza-spiro[3.3]heptane, a base and a palladium catalyst;


(d) the reaction of a compound of formula (D)



5

in the presence of trifluoromethanesulfonic anhydride and triphenylphosphine oxide;


(e) the reaction of a compound of formula (E1) or (E2)



10

in the presence of HOR, haloazetidine, 6-oxa-1-aza-spiro[3.3]heptane or HSO₂R and a base;


(f) the heating of a compound of formula (F)



in the presence of Burgess reagent;


- 137 -

(g) the heating of a compound of formula (G)




in the presence of methanesulfonic acid;

(h) the heating of a compound of formula (H)




5

(j) the heating of a compound of formula (J)




(k) the reaction of a compound of formula (K)



10


in the presence of hexachloroethane, a base and a phosphine;

(l) the reaction of a compound of formula (L)




in the presence of an oxidizing agent;

(m) the heating of a compound of formula (M)



5 in the presence of a base;

(n) the reaction of a compound of formula (N)



in the presence of a chlorinating agent and DMF; or

10 (o) the reaction of a compound of formula (C) as defined above in the presence of HSR and a base, and then an oxidation agent;

wherein A, A1 to A8 and R¹ to R⁴ are as defined in any one of claims 1 to 14 and wherein R is alkyl.

18. A compound according to any one of claims 1 to 16, when manufactured according to a process of claim 17.
- 15 19. A compound according to any one of claims 1 to 16 for use as therapeutically active substance.

20. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 16 and a therapeutically inert carrier.
21. The use of a compound according to any one of claims 1 to 16 for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, 10 cardiomypathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis.
- 15 22. The use of a compound according to any one of claims 1 to 16 for the preparation of a medicament for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, 20 acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomypathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis.
- 25 23. A compound according to any one of claims 1 to 16 for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomypathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal 30 injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis.
- 35 24. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 16 and a therapeutically inert carrier.

24. A method for the treatment or prophylaxis of pain, atherosclerosis, age-related macular degeneration, diabetic retinopathy, glaucoma, retinal vein occlusion, retinopathy of prematurity, ocular ischemic syndrome, geographic atrophy, diabetes mellitus, inflammation, inflammatory bowel disease, ischemia-reperfusion injury, 5 acute liver failure, liver fibrosis, lung fibrosis, kidney fibrosis, systemic fibrosis, acute allograft rejection, chronic allograft nephropathy, diabetic nephropathy, glomerulonephropathy, cardiomyopathy, heart failure, myocardial ischemia, myocardial infarction, systemic sclerosis, thermal injury, burning, hypertrophic scars, keloids, gingivitis pyrexia, liver cirrhosis or tumors, regulation of bone mass, 10 amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, stroke, transient ischemic attack or uveitis, which method comprises administering an effective amount of a compound as defined in any one of claims 1 to 16 to a patient in need thereof.

25. The invention as hereinbefore described.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/055797

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C07D413/14 C07D403/04 C07D413/04 A61K31/422 A61K31/4245
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2009/051705 A1 (MERCK & CO INC [US]; WU ZHICAI [US]; HARTNETT JOHN C [US]) 23 April 2009 (2009-04-23) claim 1 ----- US 2012/316147 A1 (BISSANTZ CATERINA [FR] ET AL) 13 December 2012 (2012-12-13) claim 1 ----- WO 03/082191 A2 (MERCK & CO INC [US]; FINKE PAUL E [US]; MEURER LAURA C [US]; DEBENHAM) 9 October 2003 (2003-10-09) claim 1 -----	1-25 1-25 1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
10 April 2014	28/04/2014
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Wolf, Claudia

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2014/055797

Patent document cited in search report	Publication date	Patent family member(s)	
		Publication date	
WO 2009051705	A1	23-04-2009	EP 2211619 A1 04-08-2010 US 2010227845 A1 09-09-2010 WO 2009051705 A1 23-04-2009
<hr/>			
US 2012316147	A1	13-12-2012	AR 086881 A1 29-01-2014 AU 2012266369 A1 21-11-2013 CA 2835745 A1 13-12-2012 CO 6811864 A2 16-12-2013 EP 2718266 A1 16-04-2014 TW 201311645 A 16-03-2013 US 2012316147 A1 13-12-2012 WO 2012168350 A1 13-12-2012
<hr/>			
WO 03082191	A2	09-10-2003	AU 2003225964 A1 13-10-2003 CA 2479744 A1 09-10-2003 EP 1492784 A2 05-01-2005 JP 2005531520 A 20-10-2005 US 2005182103 A1 18-08-2005 WO 03082191 A2 09-10-2003
<hr/>			